Obesity paradox in patients with cancer:

A systematic review and meta-analysis of 6,320,365 patients

Fausto Petrelli¹, Alessio Cortellini², Alice Indini³, Gianluca Tomasello⁴, Michele Ghidini³, Olga Nigro⁵, Massimiliano Salati⁶, Lorenzo Dottorini⁷, Alessandro Iaculli⁷, Antonio Varricchio⁸, Valentina Rampulla⁸, Sandro Barni¹, Mary Cabiddu¹, Antonio Bossi⁹, Antonio Ghidini¹⁰ and Alberto Zaniboni¹¹

Obesity paradox in cancer patients

1: Oncology unit, ASST Bergamo ovest, Treviglio (BG), Italy

2: Oncology unit, San Salvatore hospital, L'Aquila, Italy; Department of biotechnology and applied clinical sciences, University of L'Aquila, L'Aquila, Italy

3: Oncology unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy

4: Oncology unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

5: Oncology unit, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy

6: Oncology unit, University Hospital of Modena, Modena Cancer Centre, Modena, Italy

7: Oncology unit, ASST Bergamo est, Seriate (BG), Italy

8: Surgical oncology unit, ASST Bergamo ovest, Treviglio (BG), Italy

9: Endocrine Diseases Unit-Diabetes regional center, ASST Bergamo Ovest, Treviglio (BG), Italia

10: Oncology unit, Casa di cura Igea, Milano, Italy

11: Oncology unit, Fondazione Poliambulanza, Brescia, Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Word count: 2637

Corresponding author:

Dr. Fausto Petrelli: Oncology Unit, Medical Sciences Department, ASST Bergamo Ovest,
Piazzale Ospedale 1, 24047, Treviglio (BG) Italy

Tel. +390363424420

Fax +390363424380

Email: faupe@libero.it

Abstract

BACKGROUND. Obesity, defined as a body mass index (BMI) ≥ 30 kg/m², is associated with a significant increase in risk of many cancers. In last years, various studies suggested that obese cancer patients have better outcomes than non-obese patients. This phenomenon, also known as “the obesity paradox”, is not well understood and presents controversial explanations. We performed a systematic review and meta-analysis to assess the association between obesity and outcome after a diagnosis of cancer.

PATIENTS AND METHODS. PubMed, the Cochrane Library, and EMBASE were searched from inception to January 2020, for studies reporting prognosis of patients with obesity and cancer. Risk of death, cancer-specific survival (CSS) and progression were pooled to provide an adjusted hazard ratio with a 95% confidence interval (HR 95%CI). The primary outcome of the study refers to overall survival (OS) in obese vs non-obese patients with malignancies. Secondary endpoints were CSS and progression- or disease-free survival (PFS or RFS).

RESULTS. Mortality and relapse associated with obesity in patients with cancer were evaluated among n=6,320,365 participants (n=203 studies). Overall, association of obesity and cancer was associated with a reduced OS (HR =1.14, 95% CI: 1.09–1.19; P<.01) and CSS (HR=1.17, 95%CI 1.12-1.23; P<.01). Patients were also at increased risk for relapse (HR=1.13, 95%CI 1.07-1.19; P<.01). Patients with breast, colorectal and uterine tumors were at increased risk of death. Conversely, obese with lung cancer, renal cell carcinoma and melanoma survived longer than non-obese.

CONCLUSIONS. In many cancer patients, obesity reduces survival and increases the risk of relapse. In lung cancer, renal cell carcinoma and melanoma obesity was protective in terms of outcome. More intensive follow up, adequate dosing of oncological treatments, calories intake restrictions, physical activity and monitoring of obesity-related complications are effective measures for reducing mortality in these subjects.

Keywords: obesity, cancer, survival, meta-analysis

Introduction

Obesity, defined as a body mass index (BMI) greater than 30 kg/m², is a chronic disease with an increasing prevalence around the world, largely contributing to important health issues in most countries. Despite body fat is a general risk factor for serious illness (e.g. metabolic syndrome), greater cardiometabolic risk has also been associated with the localization of excess fat in the visceral adipose tissue and ectopic deposits¹. Several large epidemiologic studies have evaluated the link between obesity and mortality. In particular, a meta-analysis of 230 cohort studies including over 30 million individuals, found that both obesity and overweight were associated with an increased risk of all-cause mortality². Despite the evidence that excess mortality increases with increasing BMI, some studies have reached the conclusion that elevated BMI may improve survival in subjects with cardiovascular disease, a phenomenon called the "obesity paradox"³.

Increased BMI is also associated with an increased risk of multiple cancer types⁴. In addition, obesity and overweight may increase cancer mortality⁵. During last decades we also observed a more rapid increase in obesity among adult cancer survivors compared with the general population⁶. The mechanisms contributing to higher cancer incidence and mortality may include alterations in sex hormone metabolism, insulin and insulin-like growth factor levels, and adipokine pathways^{7,8}.

In last years, various studies suggested that, in cancers, patients with a normal BMI have worse outcomes than obese patients. This phenomenon (the obesity paradox) in cancer, is not well understood and presents controversial explanations^{9,10,11}. Three different meta-

analyses led to different results in particular in lung and renal cell carcinomas¹²¹³¹⁴. In lung cancer, obesity has favourable effects on long-term survival of surgical patients. Moreover, in renal cell carcinoma an inconsistent effect of BMI on cancer-specific survival was found. Conversely, breast, ovarian and colorectal cancer are invariably associated with increased mortality in obese patients¹⁵¹⁶¹⁷. The main explanations proposed to answer these observations include the general poor health status of patients with very low BMI. Additionally, weight loss may usually be associated with frailty and other risk factors (e.g. smoke)¹⁰. In cancer, obesity is also associated with increased efficacy of PD-1/PD-L1 blockade in both tumor-bearing mice and patients¹¹.

This updated systematic review and meta-analysis was conducted to evaluate the prognosis of obese vs non-obese cancer patients.

Material and methods

We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines¹⁸¹⁹.

Search strategy and inclusion criteria

A systematic search was conducted of the EMBASE, Pubmed and The Cochrane Library published from inception until January 2020. The following search terms were used: *((carcinoma or cancer or sarcoma or melanoma or ("Neoplasms"[Mesh])) AND (obese OR obesity OR 30 kg/m² OR "body mass index") AND (hazard ratio) AND survival AND (multivariate OR cox))*. The reference lists of identified articles were then manually searched to identify potentially relevant omitted citations. Articles that were not published in the English language were not included in this study.

Retrospective and observational studies (cohort, case control) or prospective trials were selected when they reported the association of obesity, defined as a BMI ≥ 30 kg/m², with the risk of death (OS), cancer-specific death (CSS) or disease-progression (PFS or DFS) in patients with cancer. We placed no restrictions on study setting, size, race or country. The inclusion was limited to studies reporting hazard ratios (HRs) and their corresponding 95% CIs. Studies were restricted to adult patients with solid tumors. Hematologic malignancies were excluded.

The most up-to-date versions of full-text publications were included. Study selection was performed in 2 stages, first, titles and abstracts were screened; then, selected full-text articles were included according to the eligibility criteria. Screening was performed independently by 10 authors (MG, GT, AG, AI, AC, ON, VR, AI, LD, MS) and conflicts were handled by consensus with a senior author (FP).

Data Collection and quality assessment

Data were collected independently by using a predesigned spreadsheet (Excel [Microsoft]). Collected data items included authors, year of publication, study setting and design, median follow up, treatments received, outcomes, and type of analysis. The primary outcome was OS, secondary endpoints were CSS and PFS/DFS. Along with data extraction, 1 author (FP) assessed study quality according to a modified Newcastle Ottawa Scale²⁰.

Statistical analysis

First, pooled HRs with 95% CIs were estimated using random effects meta-analysis with the generic inverse-variance method for studies that provided fully adjusted HRs. Inconsistency across studies was measured with the I² method. Cutoff values of 25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively. When I²

was larger than 50%, a random effects model was used; otherwise, the fixed effects model was used. Second, to examine heterogeneity, we performed analyses of predefined subgroups based on type of disease. Additionally, to address potential bias and verify our results, we performed sensitivity analysis using a leave-one-out method and the Trim and Fill method. Finally, to investigate the risk of publication bias, we applied the Egger test and visually inspected the funnel plots (begg's test). All analyses were carried out using Comprehensive Meta-Analysis software,

Results

Our literature search yielded 1,892 articles, of which 203 met the inclusion criteria for our overall systematic review of the effect of obesity on cancer outcome^{21,22,31,121–130,32,131–140,33,141–150,34,151–160,35,161–170,36,171–180,37,181–190,38,191–200,39,201–210,40,211–220,23,41,221–223,42–50,24,51–60,25,61–70,26,71–80,27,81–90,28,91–100,29,101–110,30,111–120} (Fig. 1). Most excluded studies did not use the cut-off value for obesity (BMI values different from 30 kg/m²) or used different cut-off for risk of death (e.g. 1 kg/m² of increase in BMI). Of the 203 articles, 170 were eligible for inclusion in the systematic review of the risk of obesity with OS, 109 for correlation with CSS, and 79 for correlation with DFS/PFS. Descriptive data for studies included in our meta-analysis are listed in Table 1. Overall, the included studies encompassed a total of 6,320,365 patients. Sample sizes ranged from 41 to 1,096,492 with a median of 1,543. Most studies were retrospective in nature (n=132), the minority were prospective cohort/observational studies (n=63) or pooled analysis/randomized trials (n=8).

Overall survival and obesity in cancer patients

N=170 studies reported data on OS. Because the heterogeneity test showed a high level of heterogeneity ($I^2 = 79.7\%$, $P < .01$) among studies, a random-effects model was used for the analysis. OS of obese patients was significantly worse (HR = 1.14, 95% CI: 1.09–1.19; $P < .01$; Figure 2) compared to those of not obese patients.

Cancer-specific survival and obesity in cancer patients

Similarly, obesity reduced CSS in n=109 studies (HR=1.17, 95%CI 1.12-1.23; $P<.01$; Figure 3), which reported data on cancer mortality. Heterogeneity was high ($I^2=73.9\%$), so a random effect model was used

Progression-free survival and obesity in cancer patients

Obese patients with cancer (n=79 studies) have a worse DFS/PFS than non-obese subjects (HR=1.13, 95%CI 1.07-1.19; $P<0.01$). Heterogeneity was high ($I^2=73.7\%$), so a random effect model was used.

Subgroup analysis

A subgroup analysis for OS was performed according to type of disease (Suppl. file 1), type of study (retrospective vs prospective: HR=1.07, 95%CI 1.07-1.18, $P<.01$ vs HR=1.14, 95%CI 1.05-1.23, $P<.01$), duration of follow up ($>$ vs $<$ 10 years HR=1.16, 95%CI 0.86-1.58, $P=.08$ vs HR=1.23, 95%CI 0.84-3; $P=.09$), race (Non asiatic HR= 1.22, 95%CI 0.86-1.6, $P=.06$ vs HR=1.22, 0.74-1.72, $P=.09$) and stage of disease (early vs advanced: HR=1.20, 95%CI 0.99-1.25, $P=.072$ vs HR=1.2, 95% 1.12-1.28, $P=.01$).

Publication bias

A funnel plot was used to assess publication bias in the studies evaluating OS in obese versus not obese cancer patients. No publication bias was detected (Begg's test $P=.23$). Egger's test was instead significant ($P=0.03$) (Suppl. file 2). According to the Trim and Fill method n=18 studies were placed to the left of the mean, and according the random effect model the final result was similar (HR=1.08, 95%CI 1.03-1.13). After the one study removed procedure the HR for ranged from 1.14 to 1.15.

Discussion

This meta-analysis of published (observational and retrospective) studies shows that overall mortality is increased in obese patients with breast, colorectal and uterine cancers. Cancer mortality is increased in breast, colorectal, prostate and pancreatic cancers. Finally, relapse rate is increased in breast, colorectal, prostate and gastroesophageal cancers. The “obesity paradox”, that means the apparent better cancer mortality in obese patients, is observed in lung cancer and in melanoma, despite these data derive from n=12 studies only.

Various factors are potentially linked to increased cancer mortality in some malignancies. Hormonal factors, reduced physical activity, more lethal/aggressive disease behavior, metabolic syndrome and a potential undertreatment in obese subjects are possible reasons. It is well known that postmenopausal women with higher BMI have an increased breast cancer risk due to higher estrogen levels resulting from the peripheral conversion of estrogen precursors (from adipose tissue) to estrogen²²⁴. In these patients weight loss and exercise may reduce cancer risk through lowering exposure to breast cancer biomarkers²²⁵. In colorectal cancer, BMI before diagnosis was associated with increased all-cause, cardiovascular and colorectal cancer specific mortality²²⁶. The reason of this association is presently not completely understood although insulin, insulin-like growth factors, their binding proteins, chronic inflammation, oxidative stress, and impaired immune surveillance have been supposed to be causative factors²²⁷. In pancreatic cancer higher prediagnostic BMI was associated with more advanced stage at diagnosis, with 72.5% of obese patients presenting with metastatic disease versus 59.4% of healthy-weight patients ($P = .02$) in 2 large prospective cohort studies²²². Lastly, in prostate cancer obesity may a consequence of androgen deprivation therapy but seems also related with more aggressive disease (i.e., Gleason score ≥ 7)²²⁸ or more advanced disease at diagnosis²²⁹.

Our results showed that obese lung cancer patients had significantly prolonged cancer specific survival and overall survival compared to non-obese patients. When considering these findings, we must take into account that 9 out of 11 evaluated studies included advanced/metastatic patients. Cancer cachexia mechanisms are not completely defined yet, but several evidences showed that the systemic inflammatory status induced either by the tumor and host-response is a key moment in its developing²³⁰. Lung cancers are indeed known to be aggressive diseases, and advanced patients are usually accompanied by poorer performance status and significant weight loss at the time of diagnosis, which underlies a systemic inflammatory response²³¹. According to this view, a post-hoc analysis from three international phase III studies including advanced non-small cell lung cancer patients who received a platinum-based, first-line chemotherapy, revealed that weight gain during treatment was significantly associated with better clinical outcomes²³². Intriguingly, a recent study showed that a decrease in BMI at lung cancer diagnosis (from the early adulthood) is a consistent marker of poor survival¹⁸³. Considering these observations, an increased BMI might be considered a protective feature and potentially a marker of functional reserve for lung cancer patients. Recent evidences suggest a positive predictive role of an increased BMI for cancer patients receiving immune checkpoint inhibitors across different malignancies, including lung cancer⁵⁴. Interestingly, the only study with lung cancer patients who received an immune checkpoint inhibitor (atezolizumab), revealed that the OS benefit for obese patients was significantly higher within the atezolizumab-treated cohort, compared to the docetaxel treated cohort¹¹⁰. However, we have to remark that no significant OS difference was found across BMI categories within the docetaxel treated patients. Similar mechanisms can be applied to the finding of a survival benefit for obese melanoma patients from the single included study. Several evidences indeed confirmed that a high BMI might be considered a surrogate marker of clinical benefit from immune checkpoint inhibitors for advanced melanoma patients²³³²³⁴.

Interestingly, also obese RCC patients revealed to have a significantly longer OS compared to the respective non-obese cohorts. It has been already hypothesized that the perinephric white adipose tissue act as a reservoir of activated immune cells with increased characteristics of hypoxia, infiltration of Th1 cells, regulatory T cells, dendritic cells, and type 1 macrophages. However, only one out of six studies included patient receiving immunotherapy²³⁵²³⁶.

Intriguingly, we found that the association between obesity and better clinical outcomes seems to be confirmed for those malignancies in which immune checkpoint inhibitors have first (and strongly) proved to be effective, despite studies involving patients receiving immune checkpoint inhibitors are poorly represented in this meta-analysis. Such results, might probably be an epiphenomenon, however we are allowed to speculate that the white adipose tissue could be considered an immune organ, which somehow plays a role in the anti-tumor immune response. It has been observed that the adipocyte-derived hormone leptin could alter T-cell function, resulting in improved response to anti-PD-1 therapy¹¹. Moreover, another preclinical study reported that white adipose tissue acts as a reservoir for a peculiar population of memory T cells, which elicitate some effective responses in case of antigenic re-exposure during infections (and why not in case of exposure to cancer-specific antigens?)²³⁷.

Obese patients are also at increased risk of reduced physical activity. Various studies highlighted this concept. Physical activity declines over time in obese patients²³⁸²³⁹. In particular, physical activity is strictly correlated with breast cancer and colorectal cancer mortality²⁴⁰²⁴¹. Therefore physical (in)activity should be a major target of obesity prevention and treatment in particular in cancer patients. Type 2 diabetes mellitus is strongly associated with obesity in the metabolic syndrome. More than 80 percent of cases of type 2 diabetes can be attributed to obesity, which may also account for many diabetes-related

deaths. The association between BMI and cause-specific mortality was also illustrated in the Prospective Studies Collaboration analysis²⁴². In the upper BMI range (25 to 50 kg/m²), each 5 kg/m² increase in BMI was associated with a significant increase in mortality from coronary heart disease (CHD), stroke, diabetes mellitus, chronic kidney disease, and many cancers. In the same analysis, subjects with BMI below 22.5 kg/m² had higher mortality compared with subjects with a BMI of 22.5 to 25 kg/m². The excess mortality was predominantly due to smoking-related diseases (respiratory and cancer). Despite there are no clear recommendation about dosing of chemotherapy in obese patients, caution is recommended for high risk regimens²⁴³. The hypothesis that a reduced dose according to ideal body weight may lead to a reduced outcome cannot be confirmed by prospective studies but may be considered as potential reason for the observed results in some settings (e.g. breast cancer). In a pooled analysis of toxicity in obese vs non-obese rates of toxic effects were similar or lower in obese patients²⁴⁴.

However, this meta-analysis has several limitations. First, we combined data of obese patients and compared prognosis with different non-obese subjects (normal weight or normal weight + overweight). Second, accurate measures of weight and height are always a challenge in observational studies. The evaluation is often before diagnosis but in some studies timing of obesity diagnosis is not described. Obese subjects have a general poor prognosis in term of overall mortality and non-cancer mortality, so it seems obvious that their prognosis is dismal. However, almost all studies provided a multivariate analysis according to main prognostic factor for oncological outcome so that obesity remain generally an independent prognostic factor in cancer patients. Duration of follow up, treatments received, and countries are heterogeneous even if subgroup analysis does not explain results with these different variables. Lastly, this meta-analysis compared mortality

between patients belonging to a fixed category of obesity ($>30 \text{ kg/m}^2$) and thus we are not able to provide effect size per unit increment of kg/m^2 .

In conclusion, results of this meta-analysis confirm and reinforce the notion that obesity is a competing risk factor for overall and cancer specific mortality and relapse in various cancers treated with curative intent or for metastatic disease except for lung cancer and melanoma where it has an apparent protective effect (obesity paradox). It is advised that in the future, oncologists increase their efforts to manage patients into multidisciplinary teams for care and cure of both cancer and obesity. Improving lifestyle (e.g., physical activity, calories intake, care/prevention of cardiovascular complications), more intensive follow-ups of cancer in obese, and adequate dose of medical therapies are all proved measures that may improve prognosis of obese cancer patients.

References

1. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. *Metabolism*. 2019. doi:10.1016/j.metabol.2018.09.005
2. Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: Systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. *BMJ*. 2016. doi:10.1136/bmj.i2156
3. Lavie CJ, Sharma A, Alpert MA, et al. Update on Obesity and Obesity Paradox in Heart Failure. *Prog Cardiovasc Dis*. 2016. doi:10.1016/j.pcad.2015.12.003
4. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. *BMC Public Health*. 2009. doi:10.1186/1471-2458-9-88
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. *N Engl J Med*.

2003. doi:10.1056/NEJMoa021423

6. Greenlee H, Shi Z, Sardo Molmenti CL, Rundle A, Tsai WY. Trends in obesity prevalence in adults with a history of cancer: Results from the US National Health Interview Survey, 1997 to 2014. *J Clin Oncol*. 2016. doi:10.1200/JCO.2016.66.4391
7. Gallagher EJ, LeRoith D. Obesity and diabetes: The increased risk of cancer and cancer-related mortality. *Physiol Rev*. 2015. doi:10.1152/physrev.00030.2014
8. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. *Nat Rev Cancer*. 2011. doi:10.1038/nrc3174
9. Lennon H, Sperrin M, Badrick E, Renehan AG. The Obesity Paradox in Cancer: a Review. *Curr Oncol Rep*. 2016. doi:10.1007/s11912-016-0539-4
10. Shachar SS, Williams GR. The obesity paradox in cancer-moving beyond BMI. *Cancer Epidemiol Biomarkers Prev*. 2017. doi:10.1158/1055-9965.EPI-16-0439
11. Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. *Nat Med*. 2019. doi:10.1038/s41591-018-0221-5
12. Li S, Wang Z, Huang J, et al. Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: Does the “obesity paradox” really exist? *Eur J Cardio-thoracic Surg*. 2017. doi:10.1093/ejcts/ezw386
13. Bagheri M, Speakman JR, Shemirani F, Djafarian K. Renal cell carcinoma survival and body mass index: A dose-response meta-analysis reveals another potential paradox within a paradox. *Int J Obes*. 2016. doi:10.1038/ijo.2016.171
14. Shen N, Fu P, Cui B, Bu C-Y, Bi J-W. Associations between body mass index and the risk of mortality from lung cancer: A dose-response PRISMA-compliant meta-

analysis of prospective cohort studies. *Med*. 2017.

15. Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. *Ann Oncol*. 2014. doi:10.1093/annonc/mdu042
16. Wu S, Liu J, Wang X, Li M, Gan Y, Tang Y. Association of obesity and overweight with overall survival in colorectal cancer patients: a meta-analysis of 29 studies. *Cancer Causes Control*. 2014. doi:10.1007/s10552-014-0450-y
17. Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: A systematic review and meta-analysis. *Cancer Prev Res*. 2012. doi:10.1158/1940-6207.CAPR-12-0048
18. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. In: *Journal of Clinical Epidemiology*. Vol 62. ; 2009:e1-34. doi:10.1016/j.jclinepi.2009.06.006
19. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA TS. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2010;283(15):2008-2012. doi:10.1001/jama.283.15.2008
20. Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. <http://www.ohri.ca/programs/clinical{ }epidemiology/oxford.asp>. Accessed 13 Aug 2014. *Ottawa Hosp Res Inst*. 2014.
21. Abdel-Rahman O. Pre-diagnostic body mass index trajectory in relationship to lung cancer incidence and mortality; findings from the PLCO trial. *Expert Rev Respir*

Med. 2019;13(10):1029-1035. doi:10.1080/17476348.2019.1656532

22. Abdullah A, Wolfe R, Stoelwinder JU, et al. The number of years lived with obesity and the risk of all-cause and cause-specific mortality. *Int J Epidemiol.* 2011;40(4):985-996. doi:10.1093/ije/dyr018
23. Abrahamson PE, Gammon MD, Lund MJ, et al. General and abdominal obesity and survival among young women with breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2006;15(10):1871-1877. doi:10.1158/1055-9965.EPI-06-0356
24. Abubakar M, Sung H, Bcr D, et al. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: Analysis of 3012 women from an indigenous Asian population. *Breast Cancer Res.* 2018;20(1):1-14. doi:10.1186/s13058-018-1033-8
25. Ademuyiwa FO, Groman A, O'Connor T, Ambrosone C, Watroba N, Edge SB. Impact of body mass index on clinical outcomes in triple-negative breast cancer. *Cancer.* 2011;117(18):4132-4140. doi:10.1002/cncr.26019
26. Akinyemiju T, Moore JX, Pisu M, et al. Mortality among Blacks and Whites. 2018;26(1):193-201. doi:10.1002/oby.22067.A
27. Beasley JM, Kwan ML, Chen WY, et al. Meeting the physical activity guidelines and survival after breast cancer: Findings from the after breast cancer pooling project. *Breast Cancer Res Treat.* 2012. doi:10.1007/s10549-011-1770-1
28. Aldrich MC, Grogan EL, Munro HM, Signorello LB, Blot WJ. Stage-adjusted lung cancer survival does not differ between low-income blacks and whites. *J Thorac Oncol.* 2013;8(10):1248-1254. doi:10.1097/JTO.0b013e3182a406f6
29. Alsaker MDK, Opdahl S, Åsvold BO, Romundstad PR, Vatten LJ. The association of

reproductive factors and breastfeeding with long term survival from breast cancer.

Breast Cancer Res Treat. 2011;130(1):175-182. doi:10.1007/s10549-011-1566-3

30. Arce-Salinas C, Aguilar-Ponce JL, Villarreal-Garza C, et al. Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients. *Breast Cancer Res Treat.* 2014;146(1):183-188. doi:10.1007/s10549-014-2977-8
31. Arem H, Park Y, Pelsers C, et al. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. *J Natl Cancer Inst.* 2013;105(5):342-349. doi:10.1093/jnci/djs530
32. Ata N, Ayloo S, Tsung A, Molinari M. Recipient obesity does not affect survival after deceased donor liver transplantation for hepatocellular carcinoma. A national retrospective cohort study in the United States. *Hpb.* 2019;21(1):67-76. doi:10.1016/j.hpb.2018.06.1797
33. Bandera E V., Lee VS, Rodriguez-Rodriguez L, Bethan Powell C, Kushi LH. Impact of chemotherapy dosing on ovarian cancer survival according to body mass index. *JAMA Oncol.* 2015;1(6):737-745. doi:10.1001/jamaoncol.2015.1796
34. Hung CY, Lai CC, Chen PT, et al. Impact of body mass index on long-term survival outcome in Asian populations with solid cancer who underwent curative-intent surgery: A six-year multicenter observational cohort study. *J Cancer.* 2018;9(18):3316-3325. doi:10.7150/jca.25729
35. Bassett JK, Severi G, Baglietto L, et al. Weight change and prostate cancer incidence and mortality. *Int J Cancer.* 2012;131(7):1711-1719. doi:10.1002/ijc.27414
36. Blair CK, Wiggins CL, Nibbe AM, et al. Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics. *npj Breast Cancer.* 2019;5(1):1-7. doi:10.1038/s41523-019-0128-4

37. Boggs DA, Rosenberg L, Cozier YC, et al. General and abdominal obesity and risk of death among black women. *N Engl J Med*. 2011;365(10):901-908.
doi:10.1056/NEJMoa1104119
38. Bonn SE, Wiklund F, Sjölander A, et al. Body mass index and weight change in men with prostate cancer: Progression and mortality. *Cancer Causes Control*. 2014;25(8):933-943. doi:10.1007/s10552-014-0393-3
39. Boyle T, Fritschi L, Platell C, Heyworth J. Lifestyle factors associated with survival after colorectal cancer diagnosis. *Br J Cancer*. 2013;109(3):814-822.
doi:10.1038/bjc.2013.310
40. Braithwaite D, Satariano WA, Sternfeld B, et al. Long-term prognostic role of functional limitations among women with breast cancer. *J Natl Cancer Inst*. 2010;102(19):1468-1477. doi:10.1093/jnci/djq344
41. Clark W, Siegel EM, Chen YA, et al. Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation. *J Am Coll Surg*. 2013. doi:10.1016/j.jamcollsurg.2013.01.007
42. Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. *Cancer Causes Control*. 2012. doi:10.1007/s10552-012-9989-7
43. Caan BJ, Kwan ML. Pre-diagnosis body mass index, post-diagnosis weight change. 2010;19(10):1319-1328. doi:10.1007/s10552-008-9203-0.Pre-diagnosis
44. Campbell PT, Newton CC, Newcomb PA, et al. Association between body mass index and mortality for colorectal cancer survivors: Overall and by tumor molecular phenotype. *Cancer Epidemiol Biomarkers Prev*. 2015;24(8):1229-1238.

doi:10.1158/1055-9965.EPI-15-0094

45. Carr BI, Giannelli G, Guerra V, et al. Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. *Int J Biol Markers*. 2018;33(4):423-431. doi:10.1177/1724600818776838
46. Cecchini RS, Swain SM, Costantino JP, et al. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG oncology/NSABP B-30, B-31, B-34, and B-38. *Cancer Epidemiol Biomarkers Prev*. 2016;25(1):51-59. doi:10.1158/1055-9965.EPI-15-0334-T
47. Cespedes Feliciano EM, Kwan ML, Kushi LH, et al. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer. *Cancer*. 2017;123(13):2535-2542. doi:10.1002/cncr.30637
48. Chang S, Alderfer JR, Asmar L, Buzdar AU. Inflammatory breast cancer survival: The role of obesity and menopausal status at diagnosis. *Breast Cancer Res Treat*. 2000;64(2):157-163. doi:10.1023/A:1006489100283
49. Chen X, Lu W, Zheng W, et al. Obesity and weight change in relation to breast cancer survival. *Breast Cancer Res Treat*. 2010;122(3):823-833. doi:10.1007/s10549-009-0708-3
50. Chromecki TF, Cha EK, Fajkovic H, et al. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. *BJU Int*. 2013;111(2):249-255. doi:10.1111/j.1464-410X.2012.11322.x
51. Chung IY, Lee JW, Lee JS, et al. Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer. *PLoS One*. 2017;12(3):1-11. doi:10.1371/journal.pone.0170311

52. Connor AE, Visvanathan K, Baumgartner KB, et al. Ethnic differences in the relationships between diabetes, early age adiposity and mortality among breast cancer survivors: the Breast Cancer Health Disparities Study. *Breast Cancer Res Treat.* 2016;157(1):167-178. doi:10.1007/s10549-016-3810-3
53. Conroy SM, Maskarinec G, Wilkens LR, White KK, Henderson BE, Kolonel LN. Obesity and breast cancer survival in ethnically diverse postmenopausal women: The Multiethnic Cohort Study. *Breast Cancer Res Treat.* 2011;129(2):565-574. doi:10.1007/s10549-011-1468-4
54. Cortellini A, Bersanelli M, Buti S, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable. *J Immunother Cancer.* 2019;7(1):1-11. doi:10.1186/s40425-019-0527-y
55. Crozier JA, Moreno-Aspitia A, Ballman K V., Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. *Cancer.* 2013;119(13):2447-2454. doi:10.1002/cncr.28051
56. Copson ER, Cutress RI, Maishman T, et al. Obesity and the outcome of young breast cancer patients in the UK: The POSH study. *Ann Oncol.* 2015;26(1):101-112. doi:10.1093/annonc/mdu509
57. Dahdaleh FS, Sherman SK, Poli EC, et al. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. *Surg (United States).* 2018;164(6):1223-1229. doi:10.1016/j.surg.2018.06.044
58. Dal Maso L, Zucchetto A, Talamini R, et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. *Int J Cancer.* 2008;123(9):2188-

2194. doi:10.1002/ijc.23747

59. Dalal S, Hui D, Bidaut L, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: A pilot study. *J Pain Symptom Manage*. 2012;44(2):181-191. doi:10.1016/j.jpainsymman.2011.09.010
60. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. *Clin Breast Cancer*. 2012;12(5):364-372. doi:10.1016/j.clbc.2012.07.013
61. Dickerman BA, Ahearn TU, Giovannucci E, et al. Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. *Int J Cancer*. 2017;141(5):933-944. doi:10.1002/ijc.30803
62. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: Rtog 85-31. *J Clin Oncol*. 2009. doi:10.1200/JCO.2007.12.3752
63. Dignam JJ. Obesity, Tamoxifen Use, and Outcomes in Women With Estrogen Receptor-Positive Early-Stage Breast Cancer. *CancerSpectrum Knowl Environ*. 2003;95(19):1467-1476. doi:10.1093/jnci/djg060
64. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. *J Natl Cancer Inst*. 2006;98(22):1647-1654. doi:10.1093/jnci/djj442
65. Dignam JJ, Wieand K, Johnson KA, et al. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. *Breast Cancer Res Treat*. 2006;97(3):245-254. doi:10.1007/s10549-005-9118-3

66. Doria-Rose VP, Newcomb PA, Morimoto LM, Hampton JM, Trentham-Dietz A. Body mass index and the risk of death following the diagnosis of colorectal cancer in postmenopausal women (United States). *Cancer Causes Control*. 2006;17(1):63-70. doi:10.1007/s10552-005-0360-0
67. Drake I, Gullberg B, Sonestedt E, et al. Type 2 diabetes, adiposity and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting. *Int J Cancer*. 2017;141(6):1170-1180. doi:10.1002/ijc.30824
68. Elwood JM, Tin Tin S, Kuper-Hommel M, Lawrenson R, Campbell I. Obesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort study. *BMC Cancer*. 2018;18(1):1-13. doi:10.1186/s12885-017-3971-4
69. Emaus A, Veierød MB, Tretli S, et al. Metabolic profile, physical activity, and mortality in breast cancer patients. *Breast Cancer Res Treat*. 2010;121(3):651-660. doi:10.1007/s10549-009-0603-y
70. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. *Cancer*. 2007;109(6):1192-1202. doi:10.1002/cncr.22534
71. Farris MS, Courneya KS, Kopciuk KA, McGregor SE, Friedenreich CM. Anthropometric measurements and survival after a prostate cancer diagnosis. *Br J Cancer*. 2018;118(4):607-610. doi:10.1038/bjc.2017.440
72. Fedirko V, Romieu I, Aleksandrova K, et al. Pre-diagnostic anthropometry and survival after colorectal cancer diagnosis in Western European populations. *Int J Cancer*. 2014;135(8):1949-1960. doi:10.1002/ijc.28841
73. Feliciano EMC, Kroenke CH, Meyerhardt JA, et al. Association of Systemic

Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. *JAMA Oncol.* 2017;3(12):e172319.
doi:10.1001/jamaoncol.2017.2319

74. Ferro M, Vartolomei MD, Russo GI, et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. *World J Urol.* 2019;37(3):507-514. doi:10.1007/s00345-018-2397-1
75. Froehner M, Kellner AE, Koch R, Baretton GB, Hakenberg OW, Wirth MP. A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. *BMC Urol.* 2014;14(1):1-8. doi:10.1186/1471-2490-14-28
76. Frumovitz M, Jhingran A, Soliman PT, Klopp AH, Schmeler KM, Eifel PJ. Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer. *Obstet Gynecol.* 2014;124(6):1098-1104.
doi:10.1097/AOG.0000000000000558
77. Genkinger JM, Kitahara CM, Bernstein L, et al. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. *Ann Oncol.* 2015;26(11):2257-2266. doi:10.1093/annonc/mdv355
78. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. *Cancer.* 2007;109(6):1192-1202. doi:10.1002/cncr.22534
79. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin- and obesity-related variables in early-stage breast cancer: Correlations and time course of prognostic associations. *J Clin Oncol.* 2012;30(2):164-171. doi:10.1200/JCO.2011.36.2723
80. Grossberg AJ, Chamchod S, Fuller CD, et al. Association of body composition with

survival and locoregional control of radiotherapy-treated head and neck squamous cell carcinoma. *JAMA Oncol.* 2016;2(6):782-789. doi:10.1001/jamaoncol.2015.6339

81. Sinicrope FA, Foster NR, Yothers G, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. *Cancer.* 2013. doi:10.1002/cncr.27938
82. Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. *Cancer.* 2007;110(7):1478-1484. doi:10.1002/cncr.22932
83. McMahon BJ, Bruden D, Townshend-Bulson L, et al. Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death. *Clin Gastroenterol Hepatol.* 2017. doi:10.1016/j.cgh.2016.10.012
84. Han M, Trock BJ, Partin AW, et al. The impact of preoperative erectile dysfunction on survival after radical prostatectomy. *BJU Int.* 2010;106(11):1612-1617. doi:10.1111/j.1464-410X.2010.09472.x
85. Han X, Stevens J, Truesdale KP, et al. Body mass index at early adulthood, subsequent weight change and cancer incidence and mortality. *Int J Cancer.* 2014;135(12):2900-2909. doi:10.1002/ijc.28930
86. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SCJ. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. *Ann Oncol.* 2012;23(7):1771-1780. doi:10.1093/annonc/mdr534
87. Hellmann SS, Thygesen LC, Tolstrup JS, Grønbæk M. Modifiable risk factors and survival in women diagnosed with primary breast cancer: Results from a prospective

cohort study. *Eur J Cancer Prev.* 2010;19(5):366-373.

doi:10.1097/CEJ.0b013e32833b4828

88. His M, Fagherazzi G, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Dossus L. Prediagnostic body size and breast cancer survival in the E3N cohort study. *Int J Cancer.* 2016;139(5):1053-1064. doi:10.1002/ijc.30158
89. Ho T, Gerber L, Aronson WJ, et al. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: Biology or Technique? Results from the SEARCH database. *Eur Urol.* 2012;62(5):910-916.
doi:10.1016/j.eururo.2012.08.015
90. Houdek MT, Griffin AM, Ferguson PC, Wunder JS. Morbid Obesity Increases the Risk of Postoperative Wound Complications, Infection, and Repeat Surgical Procedures Following Upper Extremity Limb Salvage Surgery for Soft Tissue Sarcoma. *Hand.* 2019;14(1):114-120. doi:10.1177/1558944718797336
91. Hu Qinchao, Peng J, Chen X, et al. Obesity and genes related to lipid metabolism predict poor survival in oral squamous cell carcinoma. *Oral Oncol.* 2019;89(December 2018):14-22. doi:10.1016/j.oraloncology.2018.12.006
92. Rosenberg L, Czene K, Hall P. Obesity and poor breast cancer prognosis: An illusion because of hormone replacement therapy. *Br J Cancer.* 2009;100(9):1486-1491. doi:10.1038/sj.bjc.6605025
93. Ruterbusch JJ, Ali-Fehmi R, Olson SH, et al. The influence of comorbid conditions on racial disparities in endometrial cancer survival. *Am J Obstet Gynecol.* 2014.
doi:10.1016/j.ajog.2014.06.036
94. Iyengar NM, Kochhar A, Morris PG, et al. NIH Public Access. 2015;120(7):983-991.
doi:10.1002/cncr.28532.Impact

95. Izumida T, Nakamura Y, Ishikawa S. Impact of body mass index and metabolically unhealthy status on mortality in the Japanese general population: The JMS cohort study. *PLoS One*. 2019;14(11):1-16. doi:10.1371/journal.pone.0224802
96. Janssen SJ, van der Heijden AS, van Dijke M, et al. 2015 Marshall Urist Young Investigator Award: Prognostication in Patients With Long Bone Metastases: Does a Boosting Algorithm Improve Survival Estimates? *Clin Orthop Relat Res*. 2015;473(10):3112-3121. doi:10.1007/s11999-015-4446-z
97. Jayasekara H, English DR, Haydon A, et al. Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. *Int J Cancer*. 2018;142(2):238-250. doi:10.1002/ijc.31049
98. Jenkins DA, Bowden J, Robinson HA, et al. Adiposity-mortality relationships in type 2 diabetes, coronary heart disease, and Cancer Subgroups in the UK Biobank, and their modification by smoking. *Diabetes Care*. 2018;41(9):1878-1886. doi:10.2337/dc17-2508
99. Jeon YW, Kang SH, Park MH, Lim W, Cho SH, Suh YJ. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. *BMC Cancer*. 2015;15(1). doi:10.1186/s12885-015-1879-4
100. Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. *Ann Oncol*. 2013;24(10):2506-2514. doi:10.1093/annonc/mdt224
101. Kaidar-Person O, Badarna H, Bar-Sela G. Bevacizumab for metastatic colon cancer: Does patient BMI influence survival? *Anticancer Drugs*. 2015;26(3):363-366.

doi:10.1097/CAD.0000000000000201

102. Kalb M, Langheinrich MC, Merkel S, et al. Influence of body mass index on long-term outcome in patients with rectal cancer-a single centre experience. *Cancers (Basel)*. 2019;11(5). doi:10.3390/cancers11050609
103. Katzmarzyk PT, Reeder BA, Elliott S, et al. Body mass index and risk of cardiovascular disease, cancer and all-cause mortality. *Can J Public Heal*. 2012;103(2):147-151. doi:10.1007/bf03404221
104. Kawai M, Tomotaki A, Miyata H, et al. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry. *Cancer Med*. 2016;5(6):1328-1340. doi:10.1002/cam4.678
105. Keegan THM, Milne RL, Andrulis IL, et al. Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: Results from the breast cancer family registry. *Breast Cancer Res Treat*. 2010;123(2):531-542. doi:10.1007/s10549-010-0774-6
106. Keizman D, Gottfried M, Ish-Shalom M, et al. Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. *Oncologist*. 2014;19(1):51-60. doi:10.1634/theoncologist.2012-0335
107. Kelly SP, Graubard BI, Andreotti G, Younes N, Cleary SD, Cook MB. Prediagnostic body mass index trajectories in relation to prostate cancer incidence and mortality in the PLCO cancer screening trial. *J Natl Cancer Inst*. 2017;109(3):1-9. doi:10.1093/jnci/djw225
108. Kenfield SA, Batista JL, Jahn JL, et al. Development and Application of a Lifestyle

Score for Prevention of Lethal Prostate Cancer. *J Natl Cancer Inst.* 2016;108(3).

doi:10.1093/jnci/djv329

109. Khan S, Cai J, Nielsen ME, et al. The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC. *Prostate.* 2017;77(8):878-887.

doi:10.1002/pros.23342

110. Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. *JAMA Oncol.* 2019.

doi:10.1001/jamaoncol.2019.5241

111. Kitahara CM, Flint AJ, Berrington de Gonzalez A, et al. Association between Class III Obesity (BMI of 40-59 kg/m²) and Mortality: A Pooled Analysis of 20 Prospective Studies. *PLoS Med.* 2014;11(7). doi:10.1371/journal.pmed.1001673

112. Minlikeeva AN, Cannioto R, Jensen A, et al. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. *Cancer Causes Control.* 2019.

doi:10.1007/s10552-019-01157-3

113. Kotsopoulos J, Moody JRK, Fan I, et al. Height, weight, BMI and ovarian cancer survival. *Gynecol Oncol.* 2012;127(1):83-87. doi:10.1016/j.ygyno.2012.05.038

114. Kristensen AB, Hare-Bruun H, Høgdall CK, Rudnicki M. Influence of Body Mass Index on Tumor Pathology and Survival in Uterine Cancer: A Danish Register Study. *Int J Gynecol Cancer.* 2017;27(2):281-288. doi:10.1097/IGC.0000000000000874

115. Kwan ML, Chen WY, Kroenke CH, et al. Pre-diagnosis body mass index and survival after breast cancer in the after Breast Cancer Pooling Project. *Breast Cancer Res Treat.* 2012;132(2):729-739. doi:10.1007/s10549-011-1914-3

116. Kwan ML, John EM, Caan BJ, et al. Obesity and mortality after breast cancer by Race/Ethnicity: The california breast cancer survivorship consortium. *Am J Epidemiol.* 2014;179(1):95-111. doi:10.1093/aje/kwt233
117. Ladoire S, Dalban C, Roché H, et al. Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: A pooled analysis of two randomised trials. *Eur J Cancer.* 2014;50(3):506-516. doi:10.1016/j.ejca.2013.11.013
118. Larsen SB, Kroman N, Ibfelt EH, Christensen J, Tjønneland A, Dalton SO. Influence of metabolic indicators, smoking, alcohol and socioeconomic position on mortality after breast cancer. *Acta Oncol (Madr).* 2015;54(5):780-788. doi:10.3109/0284186X.2014.998774
119. Siegel EM, Nabors LB, Thompson RC, et al. Prediagnostic body weight and survival in high grade glioma. *J Neurooncol.* 2013. doi:10.1007/s11060-013-1150-2
120. Lee WK, Byun SS, Kim HH, et al. Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: A multicenter study. *Int J Urol.* 2010;17(11):898-904. doi:10.1111/j.1442-2042.2010.02630.x
121. Gama RR, Song Y, Zhang Q, et al. Body mass index and prognosis in patients with head and neck cancer. *Head Neck.* 2017. doi:10.1002/hed.24760
122. Leung CC, Lam TH, Yew WW, Chan WM, Law WS, Tam CM. Lower lung cancer mortality in obesity. *Int J Epidemiol.* 2011;40(1):174-182. doi:10.1093/ije/dyq134
123. Li D, Morris JS, Day RS, Bondy ML, Abbruzzese JL. Body Mass Index and Risk , Age of Onset ,. *JAMA.* 2014;301(24):2553-2562.
124. Liss M, Natarajan L, Hasan A, Noguchi JL, White M, Parsons JK. Physical Activity

Decreases Kidney Cancer Mortality. *Curr Urol*. 2017;10(4):193-198.

doi:10.1159/000447180

125. Loi S, Milne RL, Friedlander ML, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2005;14(7):1686-1691. doi:10.1158/1055-9965.EPI-05-0042
126. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. *Lancet Oncol*. 2008;9(11):1039-1047. doi:10.1016/S1470-2045(08)70235-3
127. Maj-Hes AB, Mathieu R, Özsoy M, et al. Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. *Urol Oncol Semin Orig Investig*. 2017;35(7):460.e1-460.e8. doi:10.1016/j.urolonc.2017.01.022
128. Martini DJ, Kline MR, Liu Y, et al. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. *Cancer*. 2020;126(3):575-582. doi:10.1002/cncr.32576
129. Maskarinec G, Pagano I, Lurie G, Bantum E, Gotay CC, Issell BF. Factors affecting survival among women with breast cancer in Hawaii. *J Women's Heal*. 2011;20(2):231-237. doi:10.1089/jwh.2010.2114
130. Mathur AK, Ghaferi AA, Sell K, Sonnenday CJ, Englesbe MJ, Welling TH. Influence of body mass index on complications and oncologic outcomes following hepatectomy for malignancy. *J Gastrointest Surg*. 2010;14(5):849-857. doi:10.1007/s11605-010-1163-5
131. Matsuo K, Moeini A, Cahoon SS, et al. Weight Change Pattern and Survival

Outcome of Women with Endometrial Cancer. *Ann Surg Oncol*. 2016;23(9):2988-2997. doi:10.1245/s10434-016-5237-9

132. Song X, Pitkaniemi J, Gao W, et al. Relationship between body mass index and mortality among Europeans. *Eur J Clin Nutr*. 2012;66(2):156-165. doi:10.1038/ejcn.2011.145
133. Mazzearella L, Disalvatore D, Bagnardi V, et al. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. *Eur J Cancer*. 2013;49(17):3588-3597. doi:10.1016/j.ejca.2013.07.016
134. McCullough LE, Chen J, Cho YH, et al. DNA methylation modifies the association between obesity and survival after breast cancer diagnosis. *Breast Cancer Res Treat*. 2016;156(1):183-194. doi:10.1007/s10549-016-3724-0
135. McCullough ML, Feigelson HS, Diver WR, Patel A V., Thun MJ, Calle EE. Risk factors for fatal breast cancer in African-American women and white women in a large US prospective cohort. *Am J Epidemiol*. 2005;162(8):734-742. doi:10.1093/aje/kwi278
136. Mcquade JL, Daniel CR, Hess PKR, et al. HHS Public Access. 2018;19(3):310-322. doi:10.1016/S1470-2045(18)30078-0.The
137. Sorbye H, Mauer M, Gruenberger T, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). *Ann Surg*. 2012. doi:10.1097/SLA.0b013e3182456aa2
138. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast

cancer. *J Clin Oncol*. 2011;29(19):2645-2652. doi:10.1200/JCO.2010.33.4441

139. Meyer J, Rohrmann S, Bopp M, et al. Impact of smoking and excess body weight on overall and site-specific cancer mortality risk. *Cancer Epidemiol Biomarkers Prev*. 2015;24(10):1516-1522. doi:10.1158/1055-9965.EPI-15-0415
140. Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. *Cancer*. 2003;98(3):484-495. doi:10.1002/cncr.11544
141. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from cancer and leukemia group B 89803. *J Clin Oncol*. 2008;26(25):4109-4115. doi:10.1200/JCO.2007.15.6687
142. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from intergroup trial 0114. *J Clin Oncol*. 2004;22(4):648-657. doi:10.1200/JCO.2004.07.121
143. Møller H, Roswall N, Hemelrijck M Van, et al. Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark. *Int J Cancer*. 2015;136(8):1940-1947. doi:10.1002/ijc.29238
144. Montgomery RB, Goldman B, Tangen CM, et al. Association of Body Mass Index With Response and Survival in Men With Metastatic Prostate Cancer: Southwest Oncology Group Trials 8894 and 9916. *J Urol*. 2007;178(5):1946-1951. doi:10.1016/j.juro.2007.07.026
145. Morikawa T, Kuchiba A, Liao X, et al. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. *Int J Cancer*. 2012;131(5):1169-1178.

doi:10.1002/ijc.26495

146. Tseng CH. Obesity paradox: Differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. *Atherosclerosis*. 2013;226(1):186-192.
doi:10.1016/j.atherosclerosis.2012.09.004
147. Xie HJ, Zhang X, Wei ZQ, Long H, Rong TH, Su XD. Effect of body mass index on survival of patients with stage I non-small cell lung cancer. *Chin J Cancer*. 2017;36(1):1-10. doi:10.1186/s40880-016-0170-7
148. Nagle CM, Crosbie EJ, Brand A, et al. The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. *Gynecol Oncol*. 2018;150(1):99-105.
doi:10.1016/j.ygyno.2018.04.006
149. Nakagawa T, Toyazaki T, Chiba N, Ueda Y, Gotoh M. Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. *Interact Cardiovasc Thorac Surg*. 2016;23(4):560-566.
doi:10.1093/icvts/ivw175
150. Nechuta SJ, Shu XO, Li HL, et al. Combined impact of lifestyle-related factors on total and cause-specific mortality among chinese women: Prospective cohort study. *PLoS Med*. 2010;7(9). doi:10.1371/journal.pmed.1000339
151. Nicholas Z, Hu N, Ying J, Soisson P, Dodson M, Gaffney DK. Impact of comorbid conditions on survival in endometrial cancer. *Am J Clin Oncol Cancer Clin Trials*. 2014;37(2):131-134. doi:10.1097/COC.0b013e318277d5f4
152. Nichols HB, Trentham-dietz A, Egan KM, et al. Disease Mortality. 2010;18(5):1403-1409. doi:10.1158/1055-9965.EPI-08-1094.Body

153. Nonemaker JM, Garrett-Mayer E, Carpenter MJ, et al. The Risk of Dying from Lung Cancer by Race: A Prospective Cohort Study in a Biracial Cohort in Charleston, South Carolina. *Ann Epidemiol.* 2009;19(5):304-310.
doi:10.1016/j.annepidem.2008.12.017
154. Nur U, El Reda D, Hashim D, Weiderpass E. A prospective investigation of oral contraceptive use and breast cancer mortality: Findings from the Swedish women's lifestyle and health cohort. *BMC Cancer.* 2019;19(1):1-9. doi:10.1186/s12885-019-5985-6
155. Ogino S, Nosho K, Baba Y, et al. A Cohort study of STMN1 expression in colorectal cancer: Body mass index and prognosis. *Am J Gastroenterol.* 2009;104(8):2047-2056. doi:10.1038/ajg.2009.281
156. Oh SW, Park CY, Lee ES, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study. *Breast Cancer Res.* 2011;13(2):R34. doi:10.1186/bcr2856
157. Olson SH, Chou JF, Ludwig E, et al. Allergies, obesity, other risk factors and survival from pancreatic cancer. *Int J Cancer.* 2010;127(10):2412-2419. doi:10.1002/ijc.25240
158. Oudanoh T, Nabi H, Ennour-Idrissi K, Lemieux J, Diorio C. Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer. *Int J Cancer.* 2019;00. doi:10.1002/ijc.32621
159. Pajares B, Pollán M, Martín M, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: A pooled analysis. *Breast Cancer Res.* 2013;15(6):1-14.

doi:10.1186/bcr3572

160. Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. *Urology*. 2006;68(4):741-746. doi:10.1016/j.urology.2006.05.024
161. Parr CL, Batty GD, Lam TH, et al. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: Pooled analyses of 424 519 participants. *Lancet Oncol*. 2010;11(8):741-752. doi:10.1016/S1470-2045(10)70141-8
162. Patel GS, Ullah S, Beeke C, et al. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. *Cancer Med*. 2015;4(10):1461-1471. doi:10.1002/cam4.490
163. Pelsler C, Arem H, Pfeiffer RM, et al. Prediagnostic lifestyle factors and survival after colon and rectal cancer diagnosis in the National Institutes of Health (NIH)-AARP Diet and Health Study. *Cancer*. 2014;120(10):1540-1547. doi:10.1002/cncr.28573
164. Pfeiler G, Stöger H, Dubsky P, et al. Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: An analysis of 1509 patients of the ABCSG-06 trial. *Br J Cancer*. 2013;108(7):1408-1414. doi:10.1038/bjc.2013.114
165. Yu M-L, Asal NR, Geyer JR. Later recurrence and longer survival among obese patients with renal cell carcinoma. *Cancer*. 1991. doi:10.1002/1097-0142(19911001)68:73.0.CO;2-5
166. Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. *J Clin Oncol*. 2007;25(17):2345-2351. doi:10.1200/JCO.2006.08.6819

167. Potharaju M, Mangaleswaran B, Mathavan A, et al. Body Mass Index as a Prognostic Marker in Glioblastoma Multiforme: A Clinical Outcome. *Int J Radiat Oncol Biol Phys*. 2018;102(1):204-209. doi:10.1016/j.ijrobp.2018.05.024
168. Previs RA, Kilgore J, Craven R, et al. Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer. *Int J Gynecol Cancer*. 2014;24(4):670-675. doi:10.1097/IGC.0000000000000109
169. Prizment AE, Flood A, Anderson KE, Folsom AR. anthropometric characteristics : the Iowa Women ' s Health Study. *Cancer Epidemiol Biomarkers Prev*. 2010;19(9):2229-2237. doi:10.1158/1055-9965.EPI-10-0522.Survival
170. Probst-Hensch NM, Steiner JHB, Schraml P, et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: Association with hormonal factors and obesity. *Clin Cancer Res*. 2010;16(3):1025-1032. doi:10.1158/1078-0432.CCR-09-0957
171. Psutka SP, Boorjian SA, Moynagh MR, et al. Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. *J Urol*. 2016;195(2):270-276. doi:10.1016/j.juro.2015.08.072
172. Qi Y, Schild SE, Mandrekar SJ, et al. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. *J Thorac Oncol*. 2009;4(9):1075-1082. doi:10.1097/JTO.0b013e3181ae27f5
173. Roque DR, Taylor KN, Palisoul M, et al. Gemcitabine and Docetaxel Compared with Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma. *Int J Gynecol Cancer*. 2016;26(3):505-511. doi:10.1097/IGC.0000000000000634

174. Rudman SM, Gray KP, Batista JL, et al. Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. *BJU Int.* 2016;118(6):919-926. doi:10.1111/bju.13428
175. Sanchez A, Furberg H, Kuo F, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. *Lancet Oncol.* 2020;21(2):283-293. doi:10.1016/S1470-2045(19)30797-1
176. Sasazuki S, Inoue M, Tsuji I, et al. Body mass index and mortality from all causes and major causes in Japanese: Results of a Pooled analysis of 7 large-scale cohort studies. *J Epidemiol.* 2011;21(6):417-430. doi:10.2188/jea.JE20100180
177. Schiffmann J, Salomon G, Tilki D, et al. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. *Urol Oncol Semin Orig Investig.* 2017;35(5):243-249. doi:10.1016/j.urolonc.2016.12.014
178. Schlesinger S, Siegert S, Koch M, et al. Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis. *Cancer Causes Control.* 2014;25(10):1407-1418. doi:10.1007/s10552-014-0435-x
179. Seidelin UH, Ibfelt E, Andersen I, et al. Does stage of cancer, comorbidity or lifestyle factors explain educational differences in survival after endometrial cancer? A cohort study among Danish women diagnosed 2005–2009. *Acta Oncol (Madr).* 2016;55(6):680-685. doi:10.3109/0284186X.2015.1136750
180. Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW. Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. *Ann Intern Med.* 1992;116(1):26-32. doi:10.7326/0003-4819-116-1-26
181. Shah MS, Fogelman DR, Raghav KPS, et al. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. *Cancer.*

2015;121(17):2968-2975. doi:10.1002/cncr.29440

182. Shelke, A. R. , Roscoe, J. A. , Morrow, G. R. , Colman, L. K. , Banerjee, T. K. , &

Kirshner JJ. 基因的改变NIH Public Access. *Bone*. 2008;23(1):1-7.

doi:10.1038/jid.2014.371

183. Shepshelovich D, Xu W, Lu L, et al. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. *J Thorac Oncol*. 2019.

doi:10.1016/j.jtho.2019.05.031

184. Silventoinen K, Tynelius P, Rasmussen F. Weight status in young adulthood and survival after cardiovascular diseases and cancer. *Int J Epidemiol*. 2014;43(4):1197-1204. doi:10.1093/ije/dyu091

185. Sinicrope FA, Foster NR, Yoon HH, et al. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. *J Clin Oncol*. 2012;30(4):406-412. doi:10.1200/JCO.2011.39.2563

186. Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck TR. Association of Obesity With Tumor Characteristics and Treatment Failure of Prostate Cancer in African-American and European American Men. *J Urol*. 2007;178(5):1939-1945. doi:10.1016/j.juro.2007.07.021

187. Sparano JA, Wang M, Zhao F, et al. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. *J Natl Cancer Inst*. 2012;104(5):406-414. doi:10.1093/jnci/djr543

188. Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior

outcomes in hormone receptor-positive operable breast cancer. *Cancer*. 2012;118(23):5937-5946. doi:10.1002/cncr.27527

189. Spiess PE, Kurian T, Lin HY, et al. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. *BJU Int*. 2012;110(11 B). doi:10.1111/j.1464-410X.2012.11155.x
190. Spreafico A, Coate L, Zhai R, et al. Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. *Cancer Epidemiol*. 2017;47:28-34. doi:10.1016/j.canep.2016.11.009
191. Su HI, Sue LY, Flatt SW, Natarajan L, Patterson RE, Pierce JP. Endogenous estradiol is not associated with poor physical health in postmenopausal breast cancer survivors. *J Women's Heal*. 2013;22(12):1043-1048. doi:10.1089/jwh.2013.4375
192. Sun L, Zhu Y, Qian Q, Tang L. Body mass index and prognosis of breast cancer. *Med (United States)*. 2018;97(26). doi:10.1097/MD.00000000000011220
193. Sun X, Nichols HB, Robinson W, Sherman ME, Olshan AF, Troester MA. Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. *Cancer Causes Control*. 2015;26(12):1803-1811. doi:10.1007/s10552-015-0673-6
194. Sundelöf M, Lagergren J, Ye W. Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden. *Eur J Cancer*. 2008;44(11):1566-1571. doi:10.1016/j.ejca.2008.04.002
195. Taghizadeh N, Boezen HM, Schouten JP, Schröder CP, De Vries EGE, Vonk JM.

- BMI and lifetime changes in BMI and cancer mortality risk. *PLoS One*. 2015;10(4):1-16. doi:10.1371/journal.pone.0125261
196. Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Body mass index, diabetes, and triple-negative breast cancer prognosis. *Breast Cancer Res Treat*. 2014;146(1):189-197. doi:10.1007/s10549-014-3002-y
 197. Thrift AP, Nagle CM, Fahey PP, Smithers BM, Watson DI, Whiteman DC. Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. *Cancer Causes Control*. 2012;23(4):555-564. doi:10.1007/s10552-012-9913-1
 198. Todo Y, Okamoto K, Minobe S, Kato H. Clinical significance of surgical staging for obese women with endometrial cancer: a retrospective analysis in a Japanese cohort. *Jpn J Clin Oncol*. 2014;44(10):903-909. doi:10.1093/jjco/hyu106
 199. Trial EI, Sorbye H, Mauer M, et al. Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients. 2012;255(3). doi:10.1097/SLA.0b013e3182456aa2
 200. Trivers KF, De Roos AJ, Gammon MD, et al. Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. *Clin Gastroenterol Hepatol*. 2005;3(3):225-230. doi:10.1016/S1542-3565(04)00613-5
 201. Tsai S, Choti MA, Assumpcao L, et al. Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: A large single-institution study. *J Gastrointest Surg*. 2010;14(7):1143-1150. doi:10.1007/s11605-010-1201-3
 202. Tseng CH. Factors associated with cancer- and non-cancer-related deaths among Taiwanese patients with diabetes after 17 years of follow-up. *PLoS One*.

2016;11(12):1-16. doi:10.1371/journal.pone.0147916

203. Turner MC, Krewski D, Pope CA, Chen Y, Gapstur SM, Thun MJ. Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. *Am J Respir Crit Care Med*. 2011;184(12):1374-1381. doi:10.1164/rccm.201106-1011OC
204. Tyler CP, Whiteman MK, Zapata LB, et al. The effect of body mass index and weight change on epithelial ovarian cancer survival in younger women: A long-term follow-up study. *J Women's Heal*. 2012;21(8):865-871. doi:10.1089/jwh.2012.3487
205. Valentijn TM, Galal W, Hoeks SE, Van Gestel YR, Verhagen HJ, Stolker RJ. Impact of obesity on postoperative and long-term outcomes in a general surgery population: A retrospective cohort study. *World J Surg*. 2013;37(11):2561-2568. doi:10.1007/s00268-013-2162-y
206. Vidal AC, Howard LE, Sun SX, et al. Obesity and prostate cancer-specific mortality after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. *Prostate Cancer Prostatic Dis*. 2017;20(1):72-78. doi:10.1038/pcan.2016.47
207. Vidal AC, Howard LE, de Hoedt A, et al. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. *BJU Int*. 2018;122(1):76-82. doi:10.1111/bju.14193
208. Wang N, Khankari NK, Cai H, et al. Prediagnosis body mass index and waist-hip circumference ratio in association with colorectal cancer survival. *Int J Cancer*. 2017;140(2):292-301. doi:10.1002/ijc.30459
209. Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function

- during tumor progression and PD-1 checkpoint blockade. *Nat Med.* 2019;25(1):141-151. doi:10.1038/s41591-018-0221-5
210. Warren LEG, Ligibel JA, Chen YH, Truong L, Catalano PJ, Bellon JR. Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer. *Ann Surg Oncol.* 2016;23(12):3870-3879. doi:10.1245/s10434-016-5437-3
211. Widschwendter P, Friedl TWP, Schwentner L, et al. The influence of obesity on survival in early, high-risk breast cancer: Results from the randomized SUCCESS A trial. *Breast Cancer Res.* 2015;17(1):1-11. doi:10.1186/s13058-015-0639-3
212. Wu W, Liu X, Chaftari P, et al. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: A retrospective review. *PLoS One.* 2015;10(3):1-17. doi:10.1371/journal.pone.0122047
213. Xiao Y, Zhang S, Hou G, Zhang X, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer. *Tumor Biol.* 2014;35(3):2035-2045. doi:10.1007/s13277-013-1270-5
214. Xu H, Cupples LA, Stokes A, Liu CT. Association of Obesity With Mortality Over 24 Years of Weight History: Findings From the Framingham Heart Study. *JAMA Netw open.* 2018;1(7):e184587. doi:10.1001/jamanetworkopen.2018.4587
215. Xu H, Tan P, Zheng X, et al. Metabolic syndrome and upper tract urothelial carcinoma: A retrospective analysis from a large Chinese cohort. *Urol Oncol Semin Orig Investig.* 2019;37(4):291.e19-291.e28. doi:10.1016/j.urolonc.2018.12.005
216. Yang L, Klint Å, Lambe M, et al. Predictors of ovarian cancer survival: A population-based prospective study in Sweden. *Int J Cancer.* 2008;123(3):672-679. doi:10.1002/ijc.23429

217. Yang T, Liu K, Liu CF, et al. Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma. *Br J Surg*. 2019;106(9):1228-1236. doi:10.1002/bjs.11231
218. Yano Y, Kario K, Ishikawa S, et al. Associations between diabetes, leanness, and the risk of death in the Japanese general population: The Jichi medical school cohort study. *Diabetes Care*. 2013;36(5):1186-1192. doi:10.2337/dc12-1736
219. Yoon HH, Lewis MA, Shi Q, et al. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. *J Clin Oncol*. 2011;29(34):4561-4567. doi:10.1200/JCO.2011.37.1260
220. Yoon LS, Goodman MT, Rimel BJ, Jeon CY. Statin use and survival in elderly patients with endometrial cancer. *Gynecol Oncol*. 2015;137(2):252-257. doi:10.1016/j.ygyno.2015.01.549
221. You J, Huang S, Huang GQ, et al. Nonalcoholic fatty liver disease: A negative risk factor for colorectal cancer prognosis. *Med (United States)*. 2015;94(5):e479. doi:10.1097/MD.0000000000000479
222. Yuan C, Bao Y, Wu C, et al. Prediagnostic body mass index and pancreatic cancer survival. *J Clin Oncol*. 2013. doi:10.1200/JCO.2013.51.7532
223. Zheng J, Li Y, Zhu S, et al. NDRG4 stratifies the prognostic value of body mass index in colorectal cancer. *Oncotarget*. 2016;7(2):1311-1322. doi:10.18632/oncotarget.6182
224. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. *J Natl Cancer Inst*. 2003. doi:10.1093/jnci/djg022

225. Campbell KL, Foster-Schubert KE, Alfano CM, et al. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: Randomized controlled trial. *J Clin Oncol*. 2012. doi:10.1200/JCO.2011.37.9792
226. Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel A V., Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: The cancer prevention study-II nutrition cohort. *J Clin Oncol*. 2012. doi:10.1200/JCO.2011.38.0287
227. Renehan AG, Roberts DL, Dive C. Obesity and cancer: Pathophysiological and biological mechanisms. *Arch Physiol Biochem*. 2008. doi:10.1080/13813450801954303
228. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). *JAMA - J Am Med Assoc*. 2009. doi:10.1001/jama.2008.864
229. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. *Ann Oncol*. 2012. doi:10.1093/annonc/mdr603
230. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: Understanding the molecular basis. *Nat Rev Cancer*. 2014. doi:10.1038/nrc3829
231. Scott HR, McMillan DC, Forrest LM, Brown DJF, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. *Br J Cancer*. 2002. doi:10.1038/sj.bjc.6600466
232. Patel JD, Pereira JR, Chen J, et al. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung

- cancer patients. *Ann Oncol.* 2016. doi:10.1093/annonc/mdw211
233. Naik GS, Waikar SS, Johnson AEW, et al. Complex inter-relationship of body mass index, gender and serum creatinine on survival: Exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. *J Immunother Cancer.* 2019. doi:10.1186/s40425-019-0512-5
 234. Richtig G, Hoeller C, Wolf M, et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. *PLoS One.* 2018. doi:10.1371/journal.pone.0204729
 235. Santoni M, Cortellini A, Buti S. Unlocking the secret of the obesity paradox in renal tumours. *Lancet Oncol.* 2020. doi:10.1016/S1470-2045(19)30783-1
 236. Sanchez A, Furberg H, Kuo F, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. *Lancet Oncol.* 2020. doi:10.1016/S1470-2045(19)30797-1
 237. Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, et al. White Adipose Tissue Is a Reservoir for Memory T Cells and Promotes Protective Memory Responses to Infection. *Immunity.* 2017. doi:10.1016/j.immuni.2017.11.009
 238. Tucker JM, Tucker LA, Lecheminant J, Bailey B. Obesity increases risk of declining physical activity over time in women: A prospective cohort study. *Obesity.* 2013. doi:10.1002/oby.20415
 239. Pietiläinen KH, Kaprio J, Borg P, et al. Physical inactivity and obesity: A vicious circle. *Obesity.* 2008. doi:10.1038/oby.2007.72
 240. Spei ME, Samoli E, Bravi F, La Vecchia C, Bamia C, Benetou V. Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and

breast cancer survival. *Breast*. 2019. doi:10.1016/j.breast.2019.02.001

241. Je Y, Jeon JY, Giovannucci EL, Meyerhardt JA. Association between physical activity and mortality in colorectal cancer: A meta-Analysis of prospective cohort studies. *Int J Cancer*. 2013. doi:10.1002/ijc.28208
242. MacMahon S, Baigent C, Duffy S, et al. Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. *Lancet*. 2009. doi:10.1016/S0140-6736(09)60318-4
243. Renehan AG, Harvie M, Cutress RI, et al. How to manage the obese patient with cancer. *J Clin Oncol*. 2016. doi:10.1200/JCO.2016.69.1899
244. Hourdequin KC, Schpero WL, McKenna DR, Piazik BL, Larson RJ. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: A systematic review and meta-analysis. *Ann Oncol*. 2013. doi:10.1093/annonc/mdt294

Table

Author, Year	N° pts	N° of obese (%)	Study type	Country	Disease	Median Follow Up (months)	Disease stage	Treatment	Type of analysis	OS	CSS	DFS/PFS	Quality (NOS-METRICS)
Abdel-Rahman/2019 ²¹	145544	18131 (23.7)	Population-based randomized	US	Lung	135	Early + advanced	-	MVA	✓	-	-	12
Abdullah/2011 ²²	5036	567 (11)	Retrospective (cohort)	Various	Various	-	-	-	MVA	-	✓	-	5
Abrahamson/2006 ²³	1254	-	Retrospective	US	Breast	-	Early + advanced	-	MVA	✓	-	-	5
Abukabar/2018 ²⁴	3012	433 (13)	Retrospective	Malaysia	Breast	24	Early + advanced	S ± RT ± CT	MVA	✓	-	✓	6
Ademuyiawa/2011 ²⁵	418	164 (39.2)	Retrospective	US	Breast	37.2	Early	S	MVA	✓	-	✓	6
Akinyemiju/2018 ²⁶	22514	8786 (39)	Prospective	US	Various	78	-	-	MVA	-	✓	-	8
Aldrich/2013 ²⁸	501	126 (25.1)	Prospective (cohort)	US	NSCLC	16	Early + advanced	-	MVA	✓	-	-	7
Alsaker/2011 ²⁹	2640	432 (16.3)	Retrospective	Norway	Breast	69	Early + advanced	-	MVA	-	✓	-	7
Arce-Salinas/2014 ³⁰	819	596 (74)	Retrospective	Mexico	Breast	28	Advanced	CT	UVA	✓	-	✓	6
Arem/2013 ³¹	1400	610 (43)	Retrospective	US	Uterus	61.2	Early + advanced	-	MVA	✓	✓	-	7
Ata/2018 ³²	8352	2841 (34)	Retrospective	US	HCC	60	-	Liver transplantation	MVA	✓	✓	-	7
Bandera/2015 ³³	1846	547 (29.6)	Cohort study	US	Ovarian	-	Early + advanced	CT	MVA	✓	✓	-	5
Bassett/2012 ³⁵	16525	247 (18)	Prospective (cohort)	Australia	Prostate	180	-	-	MVA	-	✓	-	12
Beasley/2012 ²⁷	13302	2330 (17.5)	Metanalysis	US, China	Breast	-	Early	All	MVA	✓	✓	✓	-
Blair/2019 ³⁶	859	195 (22.7)	Cohort study	US	Breast	94	Early + advanced	CT, RT, HT	MVA	-	✓	-	8
Boggs/2011 ³⁷	51695	23656 (46)	Prospective	US	Various	-	-	-	MVA	-	✓	-	8
Bonn/2014 ³⁸	4376	483 (11)	Retrospective	Sweden	Prostate	48	Early	S, RT	MVA	✓	✓	✓	6
Boyle/2013 ³⁹	879	258 (29.4)	Retrospective	Australia	CRC	67.2	Early	-	MVA	✓	✓	✓	7
Braithwaite/2010 ⁴⁰	2202	500 (22.7)	Retrospective	US	Breast	88	Early	-	MVA	✓	✓	-	8
Campbell/2015 ⁴⁴	5615	1483 (26.4)	Prospective	Various	CRC	-	Early + advanced	S, CT	MVA	✓	✓	-	5
Caan/2008 ⁴³	1692	409 (24.2)	Retrospective	US	Breast	-	Early	S / adjuvant	MVA	✓	✓	✓	5
Carr/2018 ⁴⁵	521	-	Retrospective	Italy	HCC	-	Early + advanced	-	MVA	✓	-	-	5
Cecchini/2016 ⁴⁶	5265	1794 (34)	Phase III (NSABP-B30)	US	Breast	108	Early	CT	MVA	✓	-	-	-
Cecchini/2016 ⁴⁶	2102	664 (31.6)	Phase III (NSABP-B31)	US	Breast	99.6	Early	CT + TTZ	MVA	✓	-	-	-
Cecchini/2016 ⁴⁶	3311	1186 (35.8)	Phase III (NSABP-B34)	US	Breast	100.8	Early	BPS vs Placebo*	MVA	✓	-	-	-
Cecchini/2016 ⁴⁶	4860	1917 (39.4)	Phase III (NSABP-B38)	US	Breast	70.8	Early	CT	MVA	✓	-	-	-
Céspedes Feliciano/2017 ⁴⁷	2470	-	Retrospective	US	CRC	72	Early	-	MVA	✓	✓	-	7
Chang/2000 ⁴⁸	177	64 (36.2)	Retrospective	US	Breast	100	Advanced	Induction CT / S	MVA	✓	-	-	8

Chen/2010 ⁴⁹	5042	283 (5.6)	Retrospective	China	Breast	6.5	Early + advanced	S, CT, RT, HT	MVA	✓	✓	-	6
Hung/2018 ³⁴	33551	2362 (7.1)	Retrospective (cohort)	Taiwan	Solid cancers	43.8	Early + advanced	S	MVA	✓	✓	-	6
Chromecki/2012 ⁵⁰	4118	1739 (42.2)	Retrospective	Various	Bladder	44	Early	S ± adjuvant CT	MVA	✓	✓	✓	7
Chung/2017 ⁵¹	8742	75 (8.5)	Retrospective	South Korea	Breast	92	Early	All	MVA	✓	✓	-	9
Clark/2013 ⁴¹	99	40 (41)	Retrospective	US	CRC	39.4	Early	CT + RT	MVA	✓	-	✓	6
Cleveland/2012 ⁴²	1447	319 (22)	Prospective (case-control)	US	Breast	-	-	-	MVA	✓	✓	-	8
Connor/2016 ⁵²	2478	142 (5.7)	Prospective (registry)	US	Breast	129.6	Early + advanced	-	MVA	✓	✓	-	12
Conroy/2011 ⁵³	3842	901 (23)	Prospective (cohort)	US	Breast	74.4	Early + advanced	S ± CT/HT and/or RT	MVA	✓	✓	-	11
Copson/2014 ⁵⁶	2843	533 (18.7)	Prospective	UK	Breast	70.4	Early + advanced	S, RT, CT, HT	MVA	✓	-	✓	11
Cortellini/2019 ⁵⁴	976	377 (38.6)	Retrospective	Italy	Various	17.2	Advanced	Anti-PD-1/PD-L1	MVA	✓	-	✓	6
Crozier 2013 ⁵⁵	3017	1298 (43)	Retrospective	US	Breast	63.6	Early	-	MVA	-	✓	✓	8
Dahdaleh/2018 ⁵⁷	1543	529 (34.3)	Retrospective (cohort)	US	CRC	30.9	Early	S, adjuvant CT	MVA	✓	-	✓	6
Dalal/2012 ⁵⁹	41	8 (20)	Prospective	US	Pancreas	-	Advanced	CTRT	MVA	✓	-	-	7
Dal Maso/2008 ⁵⁸	1453	172 (11.8)	Retrospective	Italy	Breast	-	Early	S / adjuvant	UVA	✓	✓	-	5
Dawood/2012 ⁶⁰	2311	825 (35.7)	Retrospective	US	Breast (TN)	39	Early	S	MVA	✓	-	✓	6
Dickerman/2017 ⁶¹	5158	564 (10.9)	Retrospective	US	Prostate	-	Early	All	MVA	-	✓	-	5
Dignam/2003 ⁶³	3385	395 (11.67)	Retrospective	US	Breast	-	Early	S + HT	MVA	✓	✓	✓	5
Dignam/2006 ⁶⁴	4077	1056 (25.9)	Retrospective	US	Breast	-	-	-	MVA	✓	✓	✓	5
Dignam/2006 ⁶⁵	4288	812 (9.5)	Retrospective	North America	CRC	-	Early	CT	MVA	✓	✓	✓	5
Doria-Rose/2006 ⁶⁶	633	96 (15.2)	Retrospective	US	CRC (women)	112.8	Early	S / others	MVA	✓	✓	-	8
Drake/2017 ⁶⁷	7061	3220 (45.6)	Prospective (cohort)	Sweden	Various	202	Early + advanced	All	MVA	✓	✓	-	12
Efstathiou/2008 ⁶²	945	145 (15.3)	Prospective	US	Prostate	97.2	Advanced	RT +/- Goserelin	MVA	✓	✓	-	11
Emaus/2009 ⁶⁹	1364	147 (10.78)	Retrospective	Norway	Breast	98.4	Early + advanced	-	MVA	✓	✓	-	8
Farris/2018 ⁷¹	987	192 (19.4)	Prospective (cohort)	Canada	Prostate	228	Early + advanced	S, RT, HT	MVA	✓	✓	-	12
Fedirko/2014 ⁷²	3924	689 (17.5)	Prospective	Western Europe	Colorectal	49	Early + advanced	-	MVA	✓	✓	-	7
Feliciano/2017 ⁷³	1559	471 (30.2)	Retrospective	US	Breast	108	Early	All	MVA	-	✓	✓	8
Ferro/2018 ⁷⁴	1155	224 (21.4)	Retrospective	Italy	Bladder	48	Early	TURBT + BCG	MVA	-	✓	✓	7
Froehner/2014 ⁷⁵	2131	356 (16.7)	Retrospective	Germany	Prostate	110	Early	All	UVA, MVA	✓	✓	-	9
Frumovitz/2014 ⁷⁶	3086	1026 (33.2)	Retrospective	US	Cervical	133	Early + advanced	S, RT	MVA	✓	✓	-	9
Gama/2017 ¹²¹	1279	243 (21)	Retrospective	Canada	H&N	30	Early + advanced	RT, S, CT	MVA	✓	-	✓	6
Genkinger/2015 ⁷⁷	1096492	-	Cohort study	US	Pancreas	152.4	-	-	MVA	-	✓	-	11

Gong/2007 ⁷⁸	752	128 (17)	Retrospective	US	Prostate	116.4	Early + advanced	S / ADT / RT / others	MVA	-	✓	-	9
Gong/2012 ⁷⁰	510	51 (10)	Retrospective	US	Pancreas	121.2	Early + advanced	All	MVA	✓	-	-	9
Goodwin/2012 ⁷⁹	535	-	Retrospective	Canada	Breast	145.2	Early	S ± adjuvant CT and/or HT	MVA	✓	-	✓	9
Grossberg/2016 ⁸⁰	190	65 (34.2)	Retrospective	US	H&N	68.6	Early	CT + RT	MVA	✓	✓	✓	7
Halabi/2007 ⁸²	1296	405 (31.2)	Retrospective	US	Prostate (androgen-independent)	33.8	Early + advanced	-	MVA	✓	✓	-	6
Han/2010 ⁸⁴	2511	211 (8.4)	Retrospective	US	Prostate	156	Early	All	UVA	✓	-	-	9
Han/2014 ⁸⁵	13901	708 (5.09)	Retrospective	US	Various	-	-	-	MVA	-	✓	-	5
Xu /2018 ²¹⁵	644	92 (14.3)	Retrospective	China	Upper tract urothelial	39	Early	S	MVA	✓	✓	✓	6
He/2012 ⁸⁶	1983	546 (27.5)	Retrospective	US	Breast	47.6	Early + advanced	All	MVA	✓	-	-	7
Hellmann/2010 ⁸⁷	528	76 (14.4)	Prospective	Denmark	Breast	93.6	Early + advanced	-	MVA	✓	✓	-	10
His/2016 ⁸⁸	3160	194 (6.1)	Prospective	France	Breast	109.2	Early	-	MVA	✓	✓	✓	11
Ho/2012 ⁸⁹	1038	337 (32.4)	Retrospective	US	Prostate	41	Early + advanced	S	MVA	-	-	✓	6
Houdek/2019 ⁹⁰	261	71 (8.6)	Retrospective	-	STS	48	-	RT / none	MVA	✓	-	✓	6
Iyengar/2014 ⁹⁴	155	30 (19)	Retrospective	US	Tongue	-	Early	S	MVA	✓	✓	✓	5
Izumida/2019 ⁹⁵	10824	235 (2)	Cohort study	China	Various	220.8	-	-	MVA	-	✓	-	12
Janssen/2015 ⁹⁶	927	-	Retrospective	US	Various	-	Early + advanced	-	MVA	✓	-	-	5
Jayasekara/2018 ⁹⁷	724	164 (22.7)	Cohort study	Australia	CRC	108	Early	-	MVA	✓	✓	-	11
Jenkins/2018 ⁹⁸	502631	12539 (24.9)	Cohort study	UK	Various	93.6	-	-	MVA	✓	-	-	7
Jeon/2015 ⁹⁹	41021	1632 (4)	Prospective (registry)	Korea	Breast	92	Early	CT, HT	MVA	✓	✓	-	11
Jiralerspong/2013 ¹⁰⁰	6342	1779 (30)	Retrospective	US	Breast	64.8	Early	-	MVA	✓	✓	✓	7
Kaidar-Person/2015 ¹⁰¹	184	46 (25)	Retrospective	Israel	CRC	27.6	Advanced	CT, Bevacizumab	MVA	✓	-	✓	6
Kalb/2019 ¹⁰²	612	127 (20.7)	Retrospective	Germany	CRC	58	Early	CT, RT, S	MVA	✓	-	✓	7
Katzmarzyk/2012 ¹⁰³	10522	1972 (19)	Retrospective	Canada	Various	168	Early + advanced	All	MVA	-	✓	-	8
Kawai/2016 ¹⁰⁴	20090	897 (4.5)	Prospective (registry)	Japan	Breast	80.4	Early	CT, HT	MVA	✓	✓	✓	10
Keegan/2010 ¹⁰⁵	4153	127 (3)	Retrospective	US	Breast	-	-	-	MVA	✓	-	-	5
Keizman/2014 ¹⁰⁶	278	67 (24.1)	Retrospective	Israel	RCC	55	Advanced	TKI	MVA	✓	-	✓	7
Kelly/2017 ¹⁰⁷	7822	1612 (20.6)	Retrospective	US	Prostate	156	Early + advanced	All	MVA	-	✓	-	9
Kenfield/2016 ¹⁰⁸	112185	9984 (8.9)	Prospective	US	Prostate	170	-	-	MVA	-	✓	-	12
Khan/2017 ¹⁰⁹	822	-	Retrospective	US	Prostate	60	Early + advanced	All	MVA	-	-	✓	7
Kichenadasse/2019 ¹¹⁰	1434	239 (7)	Prospective	Various	NSCLC	-	Advanced	Atezolizumab vs Docetaxel	UVA	✓	-	✓	7
Kitahara/2014 ¹¹¹	313575	9564 (3.04)	Retrospective	Various	Various	-	-	-	MVA	-	✓	-	5

Kotsopoulos/2012 ¹¹³	1423	230 (17.5)	Retrospective	Canada	Ovarian	120	Early + advanced	All	MVA	-	✓	-	9
Kristensen/2017 ¹¹⁴	4330	-	Retrospective	Denmark	Endometrial	-	Early + advanced	S	MVA	✓	-	-	5
Kwan/2012 ¹¹⁵	14948	2440 (16.3)	Prospective (cohort)	US	Breast	93.6	Early	S ± adjuvant CT and/or HT and/or RT	MVA	✓	✓	-	11
Kwan/2013 ¹¹⁶	11351	3405 (30)	3 pooled case-control, 3 prospective cohort	US	Breast	132	Early + advanced	All	MVA	✓	✓	-	-
Ladoire/2014 ¹¹⁷	5009	666 (13.3)	Pooled analysis (2 phase III)	France	Breast	70.8	Early	CT	MVA	✓	-	✓	-
Larsen/2015 ¹¹⁸	1229	167 (14)	Prospective (cohort)	Denmark	Breast	115.2	Early	-	MVA	✓	-	-	12
Lee/2010 ¹²⁰	2750	120 (4.3)	Retrospective	South Korea	RCC	34.8	Early	S	MVA	-	✓	✓	6
Leung/2011 ¹²²	58931	3520 (5.97)	Prospective	Japan	Lung	-	-	-	MVA	-	✓	-	7
Li/2009 ¹²³	841	163 (19.38)	Retrospective	US	Pancreas	-	Early + advanced	-	MVA	✓	-	-	5
Lin/2013 ¹²⁴	799542	19988 (2.5)	Retrospective	Various	Pancreas	37.2	-	-	MVA	-	✓	-	6
Loi/2005 ¹²⁵	1101	131 (11.9)	Retrospective	Australia	Breast	60	Early	S / adjuvant	MVA	✓	-	✓	6
Ma/2008 ¹²⁶	2546	87 (3.4)	Retrospective	US	Prostate	84	Early + advanced	-	MVA	✓	✓	-	7
Maj-Hes/2017 ¹²⁷	6519	2462 (37.7)	Retrospective	Austria	Prostate	28	Early	S	MVA	-	-	✓	6
Martini/2020 ¹²⁸	90	23 (25.5)	Retrospective	US	Various	-	Advanced	IT	MVA	✓	-	✓	5
Maskarinec/2011 ¹²⁹	382	71 (18.5)	Prospective (cohort)	Hawaii	Breast	158.4	Early + advanced	S ± adjuvant CT and/or HT	MVA	✓	✓	-	12
Mathur/2010 ¹³⁰	279	97 (35)	Retrospective	US	Various	31	Advanced	Hepatectomy	MVA	✓	-	✓	6
Matsuo/2016 ¹³¹	665	459 (69)	Retrospective	US	Uterus	36.4	Early + advanced	S + CTRT	MVA	✓	-	✓	6
Mazzarella/2013 ¹³³	1250	101 (8.1)	Retrospective	Europe	Breast	-	Early	S, RT, CT	MVA	✓	-	✓	5
McCullough/2005 ¹³⁴	430236	5433 (1.3)	Prospective	US	Breast	240	Early + advanced	All	MVA	-	✓	-	12
McCullough/2016 ¹³⁵	1308	301 (23)	Population-based	US	Breast	180	Early	-	MVA	✓	✓	-	12
McMahon/2017 ⁸³	1080	-	Retrospective	US	Liver	123.6	Early + advanced	All	MVA	-	✓	-	9
McQuade/2019 ¹³⁶	1918	513 (26.7)	Pooled analysis	US	Melanoma	-	Advanced	CT, IT, TT	MVA	✓	-	✓	-
Melhem-Bertrandt/2011 ¹³⁸	1413	460 (33)	Retrospective	US	Breast (TN)	59	Early	S ± CT	MVA	✓	-	✓	7
Meyer/2015 ¹³⁹	35703	2,820 (7.9)	Population-based	Switzerland	Various	-	Early + advanced	-	MVA	✓	-	-	7
Meyerhardt/2003 ¹⁴⁰	3561	500 (16.8)	Cohort study	US	CRC	112	Early	S + CT	MVA	✓	-	✓	12
Meyerhardt/2004 ¹⁴¹	1688	306 (18)	Cohort study	US	CRC	118	Early	S + CT	MVA	✓	-	✓	12
Meyerhardt/2008 ¹⁴²	1043	236 (22.6)	Prospective	US and Canada	CRC	63.6	Early	S / adjuvant	MVA	✓	-	✓	8
Minlikeeva/2019 ¹¹²	7022	1557 (22.2)	Retrospective (pool data)	US and Australia	Ovarian	-	Early + advanced	-	MVA	✓	-	✓	5
Moller/2014 ¹⁴³	26877	4140 (15)	Cohort study	UK	Prostate	43.2	Early + advanced	-	MVA	-	✓	-	11

Montgomery/2007 ¹⁴⁴	1006	160 (16)	Retrospective	US	Prostate (androgen-dependent)	-	Advanced	Bilateral orchiectomy ± Flutamide	MVA	✓	-	✓	5
Montgomery/2007 ¹⁴⁴	671	253 (38)	Retrospective	US	Prostate (androgen-independent)	-	Advanced	Mitoxantrone/Prednisone vs Docetaxel/Estramustine	MVA	✓	-	✓	5
Morikawa/2011 ¹⁴⁵	1060	200 (19)	Prospective (cohort)	US	CRC	162	Early + advanced	All	MVA	✓	✓	-	12
Nagle/2018 ¹⁴⁸	1359	568 (41.7)	Retrospective	Australia	Endometrial	85.2	Early + advanced	S ± CT	MVA	✓	✓	-	8
Nakagawa/2016 ¹⁴⁹	1311	25 (1.9)	Retrospective	Japan	NSCLC	59	Early	S	MVA	✓	-	✓	7
Nechuta/2010 ¹⁵⁰	71243	8264 (11.6)	Cohort study	UK	Various	109.2	-	-	MVA	-	✓	-	12
Nicholas/2014 ¹⁵¹	490	203 (41.4)	Retrospective	US	Endometrial	54	Early + advanced	S	MVA	✓	-	-	6
Nichols/2009 ¹⁵²	3993	639 (16)	Retrospective	US	Breast	76.8	Early	S	MVA	✓	✓	-	7
Nonemaker/2009 ¹⁵³	2054	50 (12.5) / 46 (8.4)	Retrospective	Africa / Europe and America	Lung	-	-	-	MVA	✓	✓	-	5
Nur/2019 ¹⁵⁴	49259	202 (4.1)	Retrospective	Sweden	Breast	91.6	Early	S	MVA	✓	✓	-	8
Ogino/2009 ¹⁵⁵	546	84 (16)	Retrospective	US	CRC	-	Early + advanced	-	MVA	✓	✓	-	5
Oh/2011 ¹⁵⁶	747	251 (33.7)	Cohort study	Korea	Breast	62.2	Early	S ± CT	MVA	-	-	✓	10
Olson/2010 ¹⁵⁷	475	108 (23)	Retrospective	US	Pancreas	-	Early + advanced	S	MVA	✓	✓	-	5
Oudanonh/2019 ¹⁵⁸	3747	1790 (47.8)	Retrospective (registry)	Canada	Breast	-	Early	HT, CT, RT, antiHER2	MVA	✓	-	-	5
Pajares/2013 ¹⁵⁹	5683	1376 (24.4)	Retrospective	Spain	Breast	-	Early	CT, HT, S	MVA	✓	✓	✓	5
Parker/2006 ¹⁶⁰	970	336 (34.6)	Retrospective	US	RCC	56.4	Early	S	MVA	✓	✓	-	7
Parr 2010 ¹⁶¹	401215	16978 (4.23)	Retrospective	All	Various	-	-	-	MVA	✓	-	-	5
Patel/2015 ¹⁶²	1174	462 (39.4)	Retrospective	Australia	CRC	-	Advanced	CT	MVA	✓	-	-	5
Pelser/2014 ¹⁶³	5727	-	Retrospective	US	CRC	-	Early + advanced	S, RT, CT	MVA	✓	✓	-	5
Pfeiler/2013 ¹⁶⁴	1509	315 (21)	Retrospective	Austria	Breast	60	Early	-	MVA	✓	✓	✓	7
Pierce/2007 ¹⁶⁶	1490	380 (25.5)	Prospective	US	Breast	80.4	Early	S / adjuvant	MVA	✓	-	-	8
Potharaju/2018 ¹⁶⁷	392	40 (10.2)	Retrospective	India	GBM	48.6	-	S + RT + TMZ	MVA	✓	-	-	6
Previs/2014 ¹⁶⁸	81	28 (34)	Retrospective	US	Ovarian	-	Early + advanced	S, RT	MVA	✓	✓	✓	5
Prizment/2010 ¹⁶⁹	1096	295 (26.9)	Retrospective (registry)	US	CRC	240	Early + advanced	CT, RT, S	MVA	✓	✓	-	9
Probst-Hensch/2010 ¹⁷⁰	855	72 (19.8)	Retrospective	Switzerland	Breast	43.8	Early	S ± HT	MVA	✓	-	-	6
Psutka/2015 ¹⁷¹	387	166 (43)	Retrospective	US	RCC	86.4	Early	S	MVA	✓	✓	✓	8
Qi/2009 ¹⁷²	420	79 (22.7)	Retrospective	US	Lung	-	Advanced	All	MVA	✓	-	-	5
Qinchao Hu/2019 ⁹¹	576	33 (5.7)	Retrospective	China	H&N	64	Early	S	MVA	-	✓	✓	7
Roque/2016 ¹⁷³	128	72 (56.3)	Retrospective	US	Leiomyosarcoma	49	Early + advanced	All	MVA	✓	-	✓	6
Rosenberg/2010 ⁹²	2640	376 (14.24)	Retrospective	Sweden	Breast	-	Early + advanced	S, CT, HT, RT	MVA	-	✓	-	5

Rudman/2016 ¹⁷⁴	273	59 (21.6)	Retrospective	UK	Prostate	139.2	Early	HT	MVA	✓	✓	-	9
Ruterbusch/2014 ⁹³	627	184 (29)	Retrospective	US	Uterus	-	Early + advanced	S ± CT	MVA	✓	✓	-	5
Sanchez/2019 ¹⁷⁵	730	249 (34)	Cohort	US	RCC	-	Early + advanced	Systemic therapy + S	MVA	✓	-	-	6
Sasazuki/2011 ¹⁷⁶	353422	7327 (2)	Prospective (cohort)	Japan	Various	150	-	-	MVA	-	✓	-	12
Schiffmann/2017 ¹⁷⁷	16014	2403 (15)	Retrospective	Germany	Prostate	36.4	Early	S	MVA	-	-	✓	6
Schlesinger/2014 ¹⁷⁸	2143	397 (19)	Prospective	Germany	CRC	42	Early + advanced	-	MVA	✓	-	-	6
Seidelin/2016 ¹⁷⁹	3638	984 (27)	Population-based	Denmark	Uterus	-	Early + advanced	-	MVA	✓	-	-	7
Senie/1992 ¹⁸⁰	923	207 (22)	Prospective	US	Breast	120	Early	-	MVA	-	-	✓	12
Shah/2015 ¹⁸¹	242	59 (24.5)	Prospective	US	CRC	-	Advanced	S, CT	MVA	✓	-	-	7
Shepshelovich/2019 ¹⁸³	29217	418 (1.4)	Pooled analysis	Canada	Lung	-	Early + advanced	-	MVA	✓	-	-	-
Siegel/2013 ¹¹⁹	853	216 (25)	Prospective	US	Brain	19	Early	-	MVA	✓	-	-	8
Silventoinen/2014 ¹⁸⁴	734438	9187 (1.2)	Retrospective	Finland, Sweden	Various	403.2	-	-	MVA	✓	✓	-	9
Sinicrope/2012 ¹⁸⁵	2693	630 (23)	Randomized trial	US	CRC	-	Early	S ± CT	MVA	✓	-	✓	5
Sinicrope/2013 ⁸¹	25291	4463 (17.6)	Retrospective	US	CRC	93.6	Early	-	MVA	✓	-	✓	8
Song/2012 ¹³²	135745	-	Prospective	Europe	Various	201.6	-	-	MVA	-	✓	-	12
Sorbye/2012 ¹³⁷	342	67 (19.5)	Retrospective	Europe	CRC	-	Advanced	S ± CT	MVA	-	-	✓	-
Spangler/2007 ¹⁸⁶	924	286 (31)	Prospective	Various	Prostate	36	Early	S	MVA	-	-	✓	10
Sparano/2012 ¹⁸⁷	4817	1745 (46)	Retrospective (phase III)	US	Breast	95	Early	S + CT + HT	MVA	✓	✓	✓	-
Sparano/2012 ¹⁸⁸	6885	2547 (37)	Retrospective (3 phase III)	US	Breast	95	Early	S ± CT ± HT	MVA	✓	✓	✓	9
Spiess/2012 ¹⁸⁹	99	43 (43)	Retrospective	US	RCC	44.4	Early + advanced	S	MVA	✓	-	-	6
Spreafico/2017 ¹⁹⁰	564	76 (13)	Retrospective	Canada	Esophagus	32.5	Early + advanced	All	MVA	✓	-	✓	6
Su/2013 ¹⁹¹	1030	312 (30.3)	Randomized study	US	Breast	-	Early	S ± CT ± HT	MVA	-	-	✓	-
Sun/2015 ¹⁹²	1109	410 (37)	Population-based	US	Breast	162	Early	-	MVA	✓	✓	-	8
Sun/2018 ¹⁹³	1017	192 (18.9)	Retrospective	China	Breast	80	Early	CT, HT, RT, S	MVA	✓	-	✓	8
Sundelof/2009 ¹⁹⁴	580	55 (9.5)	Retrospective	Sweden	Esophagus	-	Early + advanced	-	MVA	✓	-	-	5
Taghizadeh/2015 ¹⁹⁵	8645	683 (7.9)	Cohort study	Netherlands	Various	480	-	-	MVA	✓	-	-	12
Tait/2014 ¹⁹⁶	501	202 (40.3)	Retrospective	US	Breast	40.1	Early + advanced	S, CT	MVA	✓	-	✓	6
Thrift/2013 ¹⁹⁷	783	263 (33)	Retrospective	Australia	Esophagus / Gastric	76.8	Early + advanced	S ± CT/RT/BSC	MVA	✓	-	-	8
Todo/2014 ¹⁹⁸	716	99 (13.8)	Retrospective	Japan	Endometrial	74	Early + advanced	S, CT	MVA	✓	✓	-	7
Trivers/2005 ²⁰⁰	1142	156 (4.2)	Retrospective	US	Esophagus / Gastric	-	Early + advanced	S / others	MVA	✓	-	✓	5
Tsai/2010 ²⁰¹	795	103 (13)	Retrospective	US	Pancreatic	-	Early + advanced	S	MVA	✓	-	-	5
Tseng/2013 ¹⁴⁶	89056	-	Prospective	Taiwan	Various	144	Early + advanced	All	MVA	-	✓	-	12
Tseng/2016 ²⁰²	92546	-	Retrospective	Taiwan	Various	204	Early + advanced	All	MVA	-	✓	-	9

Turner/2011 ²⁰³	188699	22054 (12.4)	Prospective	US	Lung	312	-	-	MVA	-	✓	-	12
Tyler/2012 ²⁰⁴	425	28 (6.6)	Prospective (case-control)	US	Ovarian	116.4	Early + advanced	All	MVA	✓	✓	-	12
Valentijn/2013 ²⁰⁵	10247	1851 (18)	Retrospective	The Netherlands	Various	64.8	-	-	MVA	-	✓	-	7
Vidal/2017 ²⁰⁶	4268	1372 (32.1)	Retrospective	US	Prostate	81.6	Early	S	MVA	-	✓	✓	8
Wang/2017 ²⁰⁸	1452	-	Retrospective	China	CRC	40.8	Early + advanced	All	MVA	-	✓	-	6
Wang/2019 ²⁰⁹	250	81 (12)	Retrospective	US	Various	-	Advanced	IT	MVA	✓	-	✓	5
Warren/2016 ²¹⁰	878	-	Retrospective	US	Breast	129.6	Early	S	UVA	-	-	✓	9
Widschwendter/2015 ²¹¹	3754	788 (21)	Phase III (SUCCESS A)	Germany	Breast	-	Early	CT + HT	MVA	✓	-	✓	-
Wu/2015 ²¹²	333	118 (35.4)	Retrospective	US	Prostate	-	Advanced	CT	MVA	✓	-	-	5
Xiao/2014 ²¹³	5785	1680 (29)	Retrospective	China	Breast	70	Early	CT, HT	MVA	✓	-	-	7
Xie/2017 ¹⁴⁷	624	-	Retrospective	China	Lung	63.2	Early	S	MVA	✓	-	-	6
Xu/2018 ²¹⁴	6197	1885 (30.4)	Cohort study	US	Various	204	-	-	MVA	-	✓	-	12
Yang/2008 ²¹⁶	635	81 (12.8)	Prospective	Europe	Ovarian	96	Early + advanced	-	MVA	-	✓	-	10
Yang/2019 ²¹⁷	2442	86 (3.5)	Retrospective	US	HCC	50.5	Early	S	MVA	✓	-	✓	8
Yano/2013 ²¹⁸	3641	792 (21.7)	Prospective	Japan	Various	122	-	-	MVA	-	✓	-	12
Yoon/2011 ²¹⁹	778	46 (19)	Retrospective	US	Esophagus (adeno)	154.8	Early	S ± adjuvant CT ± RT ± CTRT	MVA	✓	✓	✓	9
Yoon/2015 ²²⁰	2987	417 (13.9)	Retrospective (cohort)	US	Endometrial	-	Early + advanced	S, CT, RT	MVA	✓	-	-	5
You/2015 ²²¹	1314	-	Prospective (cohort)	China	Various	52.7	Early + advanced	-	MVA	✓	-	✓	10
Yu/1991 ¹⁶⁵	360	44 (12)	Retrospective	US	RCC	53	Early	S	MVA	✓	-	-	7
Yuan/2013 ²²²	902	136 (15)	Prospective (cohort)	US	Pancreas	480	Early + advanced	-	MVA	✓	-	-	12
Zheng/2015 ²²³	226	52 (23)	Cohort study	China	CRC	-	Early + advanced	-	MVA	✓	-	✓	5

*Clinical Trial Randomizing Breast Cancer Patients To Receive BFS Vs Placebo; Patients Received Concomitant Systemic Anticancer Treatment According To Physicians' Decision (Following Institutional Guidelines).

OS, Overall Survival ; CSS, Cancer Specific Survival; DFS, Disease-Free Survival; PFS, Progression-Free Survival; DDFI, Distant Disease Free Interval; US, United States Of America; UK, United Kingdom; NSCLC, Non-Small Cell Lung Cancer; HCC, Hepatocellular Carcinoma; RCC, Renal Cell Carcinoma; CRC, Colorectal Cancer; H&N, Head and Neck Tumors; STS, Soft Tissue Sarcoma; SCC, Squamous Cell Carcinoma; GBM, Glioblastoma; TN, Triple Negative; HR, Hormone Receptor; MVA, Multivariate Analysis; UVA, Univariate Analysis; S, Surgery; CT, Chemotherapy; HT, Hormone Therapy; IT, Immunotherapy; TKI, Tyrosine Kinase Inhibitor; TT, Targeted Therapy; TTZ, Trastuzumab; PD-1, Programmed Cell Death 1; PD-L1, Programmed Cell Death Ligand 1; ADT, Androgen Deprivation Therapy; BPS, Bisphosphonate; TMZ, Temozolomide; BCG, Bacillus Calmette-Guérin; RT, Radiotherapy; TURBT, Transurethral Resection of Bladder Tumor; BSC, Best Supportive Care

Tab.1: characteristics of included studies

Fig.1 flow diagram of included studies

Suppl. file 2: Funnel plot of publication bias for overall survival analysis